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General introduction 
SYSTEMIC SCLEROSIS 
Definition 
Systemic sclerosis (scleroderma, SSc) is a generalized disorder of connective 
tissue characterized by induration and thickening of the skin, by microvascular 
and larger vessel lesions, and by fibrotic degenerative changes in muscles, joints 
and viscera, mainly the esophagus, intestinal tract, heart, lungs and kidneys. These 
changes are caused by variable degrees of extracellular matrix accumulation and 
associated with specific autoantibodies, most notably anticentromere and an-
titopoisomerase I antibodies'1,2). 
History 
In the writings of both Hippocrates and Galen allusions are made to diseases of 
the skin. The first detailed report of SSc was made by the Italian physician 
Curzio, who described hardness of the skin of a 17-year-old girl in Naples in 
1753l3). The disease was given the name sclerodermie by Gintrac in 1847(4). From 
then, patients with scleroderma and widespread skin thickening were gradually 
known to have progressive internal organ disturbances. Only in 1945 did Goetz<5) 
propose the name progressive systemic sclerosis. Because not all SSc is progres-
sive, the designation progressive should be abandoned'®. 
Classification 
In 1980, a subcommittee of the American Rheumatism Association (ARA) set up 
preliminary criteria for the classification of SSc<7)(Table). 
ARA scleroderma criteria cooperative study: Preliminary criteria for the classification of 
systemic sclerosis (scleroderma) 
1. Major criterion: - Proximal scleroderma 
2. Minor criteria : - Sclerodactyly 
- Digital pitting scars or loss of substance of 
the digital finger pad 
• Bibasilar pulmonary fibrosis 
Proximal scleroderma was defined as tightness, thickening, and non-pitting 
induration proximal to the metacarpophalangeal or metatarsophalangeal joints; 
sclerodactyly as skin changes limited to fingers and toes. Digital pitting scars or 
loss of substance of the digital finger pad was defined as depressed areas at tips 
of digits or loss of digital pad as a result of digital ischemia rather than trauma or 
exogenous causes. Bibasilar pulmonary fibrosis was considered to be present 
when a bilateral reticular pattern of linear or lineonodular densities, not attribut-
able to primary lung disease, were present on standard chest X-rays. One major or 
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two or more minor criteria were found in 97% of patients with definite systemic 
sclerosis, but in only 2% of the comparison patients with systemic lupus 
erythematosus, polymyositis/dermatomyositis, or Raynaud's phenomenon. Patients 
with localized scleroderma and pseudosclerodermatous disorders were excluded'7'. 
These criteria were derived from a population of definite SSc patients and 
developed to allow comparability of patient groups in clinical (rials, not to 
diagnose SSc in the early stages. A further subclassification was proposed by 
LeRoy(8) in limited (cutaneous) SSc (ISSc) and diffuse (cutaneous) SSc (dSSc). In 
ISSc the skin involvement is limited to hands, feet, face and/or forearms; in dSSc 
skin thickening is present also on upper arms and trunk. It is currently the most 
widely used subclassification of SSc. Limited SSc is associated with a high 
incidence of anlicenlromere autoantibodies (70-80%), the existence for years of 
Raynaud's phenomenon and a significant late incidence of pulmonary hyper-
tension'". The acronym CREST (Calcinosis, Raynaud's phenomenon, oEsophageal 
dysmotility, Sclerodactyly and Telangiectasia) fits into this subclassification. 
Diffuse SSc is associated with an early incidence of interstitial lung disease, 
hypertensive crisis and renal failure, diffuse gastrointestinal disease and 
myocardial involvement"1. In approximately 30% of dSSc patients antitopo-
isomerasc I autoantibodies can be detected"012'. 
Epidemiology 
The rarity of SSc makes it a difficult disorder to study epidemiologically. It has 
been described in all races and is global in its distribution. Most of the available 
data concerning incidence are derived from records of patients attending hospitals 
draining a defined denominator population. Its incidence is suggested to be in 
between 4 and 12 individuals per million population per year"3141. The disease 
seldom occurs in childhood"5161, is 3 - 4 times more common in women than men 
and its onset is highest in the fourth and fifth decade of life"71. The incidence of 
SSc seems to be increasing"41, probably because of better ascertainment. 
Prognosis 
The natural course of the disease is variable: a few patients experience spon-
taneous remission; the majority undergoes progression of skin and internal organ 
involvement, resulting in considerable morbidity and mortality"8"1. Several 
studies report 5-year cumulative survival rates ranging from 34-73%(20). Older age, 
male gender, internal organ involvement, presence of antitopoisomerase I autoan-
tibodies, and diffuse skin involvement adversely affect outcome'21 ^1. 
Etiology 
Although the etiology of SSc is still unknown, genetic and environmental factors 
appear to play a part'241. The familial and genetic predisposition to SSc is indi-
cated by its occurrence predominantly in the female sex"7,251, the reported familial 
clusterings of SSc'26,271 and related diseases'281, and by the fact that autoantibodies 
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associated with SSc are found frequently in blood from relatives of patients with 
SSc<29). Studies concerning the pattern of the major histocompatibility complex 
(MHC) antigens in scleroderma patients have led to conflicting results from the 
different geographic areas in which they have been performed'30'. In the Dutch 
population an increased incidence of the haplotype HLA Al, B8 and DR3 was 
found'3". The Finding of an abnormal fibronectin gene in Japanese patients, 
suggesting a gene defect as cause of SSc, could not be confirmed in Dutch 
patients'32'. Some chemicals, such as toluene and benzene'33', irichloroethylene'33', 
and organic solvents'34' are associated with systemic-like conditions. Likewise, ex-
posure to vinylchloride'35', epoxy resins'16', silica dust'37' and aniline-adulterated 
rape seed oil'38', and treatment with drugs such as pentazocine'3", L-tryptophan 
and carbidopa'40' and bleomycin'4" may cause scleroderma-like disease. Microvas-
cular lesions associated with the development of fibrosis'42' or direct stimulation of 
collagen production'4043' have been mechanisms proposed for the sclerodermatous 
changes. 
SSc has also been reported to occur among recipients of silicone breast 
implants'44'. However, the cause-effect relationship is unknown and there are no 
concrete data as to whether the removal of silicone implants will halt the pro-
gression of the disease. 
Finally, the chronic graft-versus-host reaction, developing after allogenic bone 
marrow transplantation, can cause sclerosis of the skin, muscles and bones'45'. 
At present, there is no adequale expérimental model that reproduces all the 
characteristics of SSc. Skin changes resembling scleroderma occur in a mutant 
line of white leghorn chickens, the so called UCD L-200 line'46', and in the light-
skin mouse'47'. Both animal models lack internal organ involvement. 
Pathogenesis 
Although the pathogenesis of SSc remains unknown, the altered connective tissue 
metabolism, vascular abnormalities and changes in the immune system all seem to 
be involved. 
a. Altered connective tissue metabolism 
The deposition of increased amounts of extracellular matrix components (collagen, 
fibronectin, and glycosaminoglycans) is a hallmark of systemic sclerosis. Tissue 
cultures of dermal fibroblasts have been found to synthesize collagen at an 
increased rate'4*"50' and to accumulate up to 5 times more glycosaminoglycans than 
normal skin fibroblasts'51'54'. Likewise, an increase in fibronectin in the deep 
dermis of involved skin in progressive systemic sclerosis was found'55'. 
The increase of collagen production is likely to be the result of an increased rate 
of biosynthesis since both collagenase activity and collagen degradation is normal 
in cultured scleroderma fibroblasts. The mechanisms through which scleroderma 
fibroblasts are stimulated to produce more extracellular matrix are unknown; it is 
suggested that some factors from sera or cells, such as platelet derived growth 
factor, interleukins 1 and 4, and fibroblast growth factor, promote a high collagen 
producing fibroblast population'56'. 
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b. Vascular abnormalities 
Vascular lesions are widespread in SSc and often considered to be the primary 
event(57). Evidence for vascular dysfunction is demonstrated by the presence of 
Raynaud's phenomenon as indicator of vasomotor instability in up to 90% of 
scleroderma patients and the microvascular abnormalities characterized by arterial 
intimai proliferation leading to irregular luminal narrowing and zones of total 
obstruction. The presence of abnormal nailfold capillaries can be demonstrated in 
more than 80% of scleroderma patients'58'. Endothelial cell damage seems to be 
the central event and is reflected by changes in circulating levels of endothelial 
cell products such as von Willebrand factor, plasminogen activating factor, and 
prostacyclin/thromboxane metabolites. This damage may lead to altered per­
meability of the vessel wall and increased passage of mononuclear cells. Possible 
explanations of endothelial cell damage in SSc are exposure to endothelial cell 
cytotoxins produced by activated T-cells'59'6" or complement activation due to 
reduced expression of the cytoprotectivc proteins CD 59 and decay accelerating 
factor on the endothelial cell surface'62'. 
с Autoimmune alterations 
- Aberrant humoral immune responses 
About 95% of SSc-patients have detectable antinuclear antibodies when HEp-2 
cell lines are used as the detection substrate'63'. Anticentromere autoantibodies are 
directed against the centromere of chromosomes and are detected in sera of 
approximately 30% of unselected scleroderma patients. Anticentromere autoanti­
bodies have a predilection for patients with limited cutaneous involvement. 
Patients with anticentromere autoantibodies and only Raynaud's phenomenon have 
an increased risk of eventually developing limited SSc eventually'64'. Antitopo-
isomerase I autoantibodies are directed against the enzyme topoisomcrase I which 
modulates the topological states of DNA. They occur in about 20% to 50% of 
SSc patients and are associated with diffuse cutaneous involvement. Antitopo-
isomerase I autoantibodies were originally designated anti-Scl 70 or anti-Scl 86"0>, 
and are associated with more frequent occurrence of internal organ invol­
vement'65'. 
Other nucleolar autoantibodies detected in less than 10% of patients with SSc are 
anti-RNA polymerase I and III antibodies, anti-Th-antibodies, anti-Ul RNP- and 
anti-U3 RNP antibodies and anti-PM-Scl antibodies. 
Other circulating antibodies to self proteins frequently detected in SSc and mainly 
in the early stages of the disease are antibodies against type I, II, IV and VI 
collagen; these antibodies are associated with the severity of interstitial lung 
disease'66'. 
Whether the production of autoantibodies is important in the pathogenesis of SSc 
or whether they are mainly 'innocent bystanders' is still a subject of debate. 
- Aberrant cell-mediated immune responses 
Τ lymphocytes and plasma cells are found in excess in the involved skin during 
the early course of the disease'67'. In the peripheral blood, the number of Τ cells is 
decreased with a normal ratio of Τ to В cells but the ratio of helper Τ cells to 
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suppressor Τ cells is increased in approximately 30% of the patients'68"70*, mainly 
because of a reduction in suppressor Τ cells'67,6". The number of natural killer 
cells in peripheral blood of SSc patients appears to be normal'70 but the activity 
of these cells is reduced, predominantly in patients with active disease and wides­
pread visceral involvement'72,73'. Scleroderma mononuclear cells spontaneously 
release interleukin 1 (IL-1) and T-cell response to IL-1 is defective'74'; IL-1 
production by mononuclear cells is reduced'75'. Serum levels of interleukin-2 (IL-
2) and IL-2 receptors are increased'76"80' and correlate positively with skin thick-
ness'
81
*
2
'. 
The changes known to occur in connective tissue metabolism, vascular 
endothelium and immune system have led to several hypothetical schemes of the 
pathogenesis of systemic sclerosis, in which an unknown inciting event breaks 
down endothelial cells and activates the immune system. The activated immune 
system enhances endothelial cell damage which results in release of cytotoxic 
products causing fibroblast proliferation and enhanced extracellular matrix 
deposition with, ultimately, fibrosis'83'. 
Treatment 
Many drugs have been advocated in the treatment of SSc, but none has been 
proven to be effective in properly controlled trials. In assessing efficacy of a drug 
in SSc, the variable disease course with sometimes spontaneous improvement after 
several years, and variable rate of progression of SSc make it necessary to 
perform double-blind, preferably placebo controlled trials. Such double-blind 
therapy trials are limited in systemic sclerosis and have not provided evidence of 
benefit in systemic manifestations. 
Based upon a belter understanding of the pathogenesis of SSc, therapeutic trials 
have focussed on drugs affecting vascular changes, collagen and other extracel­
lular matrix components produced by fibroblasts, and immunologic changes. 
Drugs aimed at improvement of the vascular pathology include aspirin, dipyridam­
ole, ketanserin and iloprost'84"86'. These treatments can improve Raynaud's 
phenomenon and digital ulcers but were not found to improve skin thickening or 
stop organ damage. They arc less likely to be effective once vessels arc totally 
occluded. 
Drugs aimed at inhibition of formation of collagen and other extracellular matrix 
components by fibroblasts arc D-penicillamine, colchicine, cyclofenil, N-Acetyl-
cysteine and interferon-γ. D-penicillamine is able to cleave the labile cross-links 
of newly formed collagen and is currently the most widely used treatment of SSc 
although its presumed efficacy has never been tested in a double-blind trial. 
Retrospective studies showed improvement in skin thickening and improved 5-
year survival compared to similar historical controls'87,88'. A multicentcr double-
blind trial is under way comparing 750 mg D-penicillamine with 62.5 mg D-
penicillamine per day'89'. Cyclofenil inhibits production of proteoglycans and was 
reported to produce slight changes in skin softening in two controlled trials but 
allergic and hepatic reactions limit its use'9 0"'. N-Acetylcysteine, which is 
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presumed to promote collagen breakdown, was shown to be ineffective in a 
double-blind trial'"' and the evaluation of colchicine, which affects collagen 
deposition, gave conflicting results"3'. Interfcron-γ and interferon-α inhibit fibro­
blast proliferation and collagen production. Interferon-γ gave promising results in 
open uncontrolled trials'*4"96' while interferon-α seemed less effective"7'. 
Drugs aimed at affecting immunologic changes, such as azathioprine, cyclophos­
phamide and cyclosporine A have been studied in several uncontrolled trials"8'. 
Although cyclosporine A gave promising results, the high frequency of renal 
toxicity limits its use in SSc"9"100'. 
Chlorambucil00" and S-fluorouracil002' have been shown not to be superior to 
placebo in double-blind trials. Photopheresis was compared with D-penicillamine 
in a single-blind multicenter controlled trial003'. Although photopheresis was 
reported to be superior to D-penicillamine, the conclusions of this study have been 
doubted by others00*105'. 
Outcome measures in systemic sclerosis 
Various outcome measures have been used in clinical trials of SSc. These 
measures include skin scores (determining the area and degree of the skin 
involved on a three- or four point scale)006,87', physical function using the HAQ 
disability scale or the functional index, global assessments by patient or physician 
and physical performance assessments such as maximal oral opening, flexion and 
extension index (distance between third finger and the distal palmar crease in full 
flexion respectively extension), grip strength007'. Outcome measures concerning 
visceral involvement comprise pulmonary function tests and chest X-rays, barium 
swallow of the oesophagus and oesophageal manometry or scintigraphy, creatinine 
clearance, electrocardiograms, echocardiograms and Holter monitoring007'. Many 
of these outcome measures did not detect significant differences between a presu­
med active drug and placebo in double-blind trials, although this could be 
explained by the inefficacy of the treatments used. 
Although mortality is an important endpoint in SSc, significant differences are 
unlikely to be found between treatment groups in trials of less than three years 
duration. In a recent review dealing with outcome measurements for treatments of 
scleroderma patients in clinical trials Pope and Bellamy concluded that skin score 
measurements and global assessment are the best primary outcome measures for 
clinical trials; good secondary measures include variables of internal organ invol­
vement, mortality, functional assessment, and physical parameters such as grip 
strength and extension index"07'. 
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METHOTREXATE 
Methotrexate (4-amino-4 deoxy-N10-methylpteroylglutamic acid, MTX) resembles 
folic acid and is an inhibitor of folate dependent enzymes such as dihydrofolate 
reductase (DHFR), 5 aminoimidazole-4-carboxamide ribonucleotide, thymidine 
synthetase and glycinamide ribonucleotide transformylase"01". These enzymes are 
involved in the pyrimidine (DNA) synthesis and the de-novo purine synthesis of 
DNA and RNA"09·110'. DHFR is the major of these enzymes and its inhibition by 
MTX leads to depletion of tctrahydrofolates, that are essential for DNA, RNA and 
protein synthesis. 
MTX is absorbed rapidly and completely after dosages not exceeding 30 mg/m2 
(109.110)
 an(j j|f[er absorption, fifty to seventy percent is bound to plasma proteins, 
mainly albumin. MTX is transported via an active carrier-mediated system into 
the hepatic cells"09'110', where it is converted to MTX polyglutamates. At low 
doses, such as used in rheumatic diseases, MTX is not subjected to much meta-
bolism and 80 to 90% is excreted by the kidneys. MTX is also secreted in the 
bile, but most of it is reabsorbed. When renal function is impaired, biliary excre-
tion is increased01". 
Low-dose MTX is a widely accepted treatment of rheumatic diseases such as 
rheumatoid arthritis"12'"5', poly- and dermatomyositis"16"7'. Dosages administered 
in these diseases vary from 7.5 mg/week to 50 mg/week in one single dose or 
divided into three fractional doses at 12-hour intervals. Low-dose MTX has also 
been reported to be effective in SLE"18'20', periarteritis nodosa'l21·122' and We-
gener's granulomatosis"2". The mechanisms by which low dose MTX affects the 
inflammatory process in rheumatic disease remain poorly understood; most studies 
of immune function in RA patients treated with low dose MTX show only 
marginal effects on humoral or cellular immune responses and the rapid clinical 
response to treatment as well as the equally rapid flare of disease subsequent to 
its discontinuation suggests an anti-inflammatory effect"24'. A recent study sug-
gested inhibition of synovial fibroblast proliferation to be a possible action of 
MTX in rheumatoid arthritis"25'. 
Adverse reactions of MTX mainly comprise gastrointestinal complaints, 
gastrointestinal ulceration and hemorrhage and elevation of liver enzymes ( ,26· ,27). 
There is no evidence of increased liver toxicity after 2 grams MTX in rheumatoid 
arthritis patients"28'. MTX pneumonitis is a seldom occurring, though life threaten-
ing, complication of MTX therapy and has not been related to the cumulative 
dose, age or route of administration"2"30'. Hematological toxicity (leucopenia, 
thrombocytopenia, megaloblastic anaemia, pancytopenia) occurs in approximately 
3% of patients treated with low-dose MTX"3" and seldom occurring side effects 
include dermal toxicity"32' and increased susceptibility to infections"33'. 
Chapter I 
METHOTREXATE AND SYSTEMIC SCLEROSIS 
Low-dose MTX as a treatment for patients with SSc has been described only in 
one report034'. It concerned two patients, one suffering from limited SSc and the 
other from diffuse SSc complicated by pulmonary fibrosis. The dosage used was 
25 mg MTX biweekly over a period of 6 months. In both patients improvement 
was obtained as assessed by amelioration of the general condition, Raynaud's 
phenomenon and skin thickening. For unknown reasons, this report has never 
been quoted in the literature concerning treatment of SSc. 
AIM AND CONTENTS OF THIS THESIS 
The major objective of this thesis is to determine the efficacy and toxicity of low-
dose MTX in the treatment of patients suffering from systemic sclerosis. 
In chapter Π the literature on immunomodulating therapy is reviewed. 
In chapter Ilia the first two scleroderma patients that received MTX in our 
department are described; in chapter Illb we report on the data of an open study 
in which eight patients with SSc were treated with MTX. 
The results of a randomized, double-blind, placebo controlled trial comparing low-
dose MTX with placebo are described in chapter IV. 
Chapter V comprises the effects of low-dose MTX on glycosaminoglycan 
synthesis by scleroderma fibroblast in culture. 
The development of a recombinant topoisomerase for application in an ELISA is 
described in chapter VI. 
Chapter Vila offers changes in antitopoisomerase I antibody titers during 
plasmapheresis in a patient with SSc, and chapter Vllb deals with effects of MTX 
on antitopoisomerase I antibody titers, measured in patients involved in the 
double-blind trial. 
In chapter VIII the evolution from MCTD to SSc, SLE, RA or a combination of 
these diseases in patients with anti-(Ul)snRNP antibodies is described. 
Finally, a summary of the results and the conclusions is offered in chapter IX. 
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Immunomodulatory treatment of systemic sclerosis 
Summary 
We reviewed studies concerning immunomodulating therapy in systemic sclerosis. 
These comprise mostly uncontrolled trials and case reports. Some of these studies 
hint at a possible beneficial effect of antimetabolites (azathioprine. 5-fluoro-uracil 
and methotrexate), cyclosporin and interferon-·^. However, to give a clearcut 
answer on the efficacy of these drugs in systemic sclerosis, controlled studies are 
urgently needed. 
Introduction 
Systemic sclerosis (SSc) is a multisystemic disease with characteristic vascular 
lesions and fibrosis of the skin, synovium, muscles and internal organs, notably 
the gastrointestinal tract, lung, heart and kidney0'. The ctiopathogenesis of the 
disease is unknown, but a role for (auto)immune mechanisms is suggested by the 
wide range of autoantibodies found in at least 90% of SSc patients'2·3', the 
accumulation of Τ cells and an elevated Τ helper/T suppressor ratio in skin 
biopsy specimens due to a decrease in the number of suppressor cells'451. 
Evaluation of treatment of this disorder has been difficult because of the variable 
course in the individual patient with occasional spontaneous remissions, and the 
unavailability of objective parameters on which to assess clinical improvement 
No single drug or combination of drugs has proved to be of value in adequately 
controlled studies(6>; the literature on this subject comprises mostly retrospective or 
uncontrolled studies and case reports. 
In view of the presumed immune-mediated pathogenesis of systemic sclerosis, 
drugs with immunoregulatory activities have also been used in the treatment of 
patients with SSc. If one excludes corticosteroid therapy, these drugs consist of 
alkylating agents, purine antimetabolites, cyclosporine and interferon-γ. Experi­
ence with these drugs in the treatment of SSc will be briefly reviewed. 
Alkylating agents 
Chlorambucil 
Mackenzie0" treated 11 patients with chlorambucil (0.1 mg/kg a day) for 18 
months and noted absence of further progression in every organ system studied, 
with healing of all fingertip ulcers and increased finger movements. There was 
also improvement in pulmonary function studies in 6 patients. Anscll ct al.(8>, 
using chlorambucil in doses between 4 and 7 mg daily in the treatment of a 15-
year-old girl, noticed prolonged considerable loosening of the skin and improve­
ment of the flexion contractures, even after discontinuation of the drug. These 
encouraging results could not be substantiated by Steigerwald"', who treated 27 
patients with the same dosage of chlorambucil: seven patients died after 2 to 37 
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months of therapy (two from renal disease and five from progressive cardiorespi-
ratory involvement); the remaining patients showed no evidence of any regression 
or even stabilization of the disease except for improvement in myositis and 
arthritis. Saporta et al.(l0), using 0.2 mg/kg a day during 2 years in two patients, 
found no changes in sclerotic skin or systemic manifestations, and an extensive 
double blind placebo-controlled study with 0.05-0.1 mg/kg a day by Fürst et al.(1,), 
conducted over a 3-year period in 65 patients, failed to show significant differ-
ences between treatment groups. 
Cyclophosphamide 
Cyclophosphamide has been reported incidentally in the treatment of a day for 6 
months without any effect, and Chaouat et al.(12) treated two patients with cyclo-
phosphamide: one showed some clinical improvement while the other did not 
(data on cyclophosphamide dosage and duration of therapy were not given). 
Hurd and Giuliano"5' studied the effect of therapeutic cyclophosphamide 2 mg/kg 
a day. They found a reduction of both В and Τ lymphocytes as early as 2 weeks 
after onset of treatment in each case, with eventual depletion of both cell types, 
but no data are reported of any effect on the disease itself. 
Tolchin et al.(l4) observed a significant increase in the number of cytogenic 
aberrations in five patients during therapy with cyclophosphamide, 2 mg/kg a day, 
ranging from 2-25 months; again no mention was made of any effect on the 
disease itself. 
In an uncontrolled trial Dau et al.<l5) found a combination of plasmapheresis with 
prednisone and cyclophosphamide therapy to produce clinical improvement in 14 
of 15 patients with varying degrees of skin and internal organ involvement. The 
extent to which cyclophosphamide might have contributed to this improvement 
remains unclear. 
Kaplan and Ward"6' found a combination of plasmapheresis, steroids and cyclo­
phosphamide effective in reversing previously irreversible serious gastrointestinal 
and pulmonary complications of SSc in five patients. 
To separate effects of combined plasmapheresis and immunosuppression from 
immunosuppression alone, Wollhcim and Àkesson(l7) started immunosuppression 
(cyclophosphamide 2 - 2,5 mg/kg during the first year and azathioprine during the 
second year) in seven patients, and combined therapy in eight; all patients 
received prednisolone at the same time. Although far from conclusive, their 
results showed a tendency in favor of the combined group. 
Anti-metabolites 
6-Thioguanine 
Demis et al."e> were the first to report in 1964 the use of an anti-metabolite in the 
treatment of SSc; they used a daily dose of 1 mg/kg 6-thioguanine for two weeks 
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each month in two patients. After 6 rcsp. 8 months of treatment they found no 
clear, objective evidence of significant prolonged improvement, although both 
patients did report softening of the skin; two years after discontinuation of the 
drug no progression of the disease was noted. 
Azathioprine 
Jansen et al."" treated 21 patients with azalhioprine, 150 mg a day for 5 to 23 
months; eight patients were judged to have improved subjectively and by clinical 
evaluation during the course of the treatment, seven were unchanged and two 
showed progression of their disease. One patient was lost to follow-up; three had 
to discontinue the drug because of side effects. These uncontrolled results were 
said to be slightly better than those observed in other groups of untreated patients. 
Kurwa and Denman'2"' reported on one patient using a maintenance dose of 150 
mg azathioprine on weekdays in combination with 10 mg prednisone daily. They 
found improvement in the range of joint motion and some softening of the skin 
on arms and legs. 
Saporta et al.<l0) treated two patients with the acrosclcrotic form of SSc with 2.5 to 
3 mg azathioprine/kg a day during 5 and 17 months respectively; no effect on the 
sclerodermatous skin or visceral manifestations could be observed. 
Thivolel and Perrot(î" noted no effect of 6-mcrcaptopurine, a metabolite of 
azathioprine (total dose 5250 mg in 34 days), and minor improvements in skin 
hardening but deterioration of pulmonary function tests after treatment with 
azathioprine (total dose 2165 mg in 3 months) in two patients. 
Maas et al.(22) reported on 19 patients who received 2-2.5 mg azathioprine/kg 
daily. In 16 cases no further progression of the disease was noted, in particular no 
further deterioration in lung and kidney manifestations. One patient showed minor 
deteriorations and two died: one from osteomyelofibrosis УА years after azathio­
prine had been discontinued, the other from right heart failure after recurrent 
pulmonary emboli. The authors stated that, on the whole, therapy with azathio­
prine over a long period of time seems in most cases to prevent further pro­
gression of the disease. 
5-Fluoro-uracil (5-FU) 
Casas et al.(Z" treated 12 patients with 12.5 mg 5-FU/kg a day intravenously (IV) 
in 4 - 5 doses, followed by 4 additional doses (8-10 mg/kg/day) given IV every 
two days, followed by a weekly dose of 10-20 mg/kg IV. Significant and objec­
tive improvement occurred initially in the skin and subsequently in the involved 
viscera and vasculature. The authors suggested that 5-FU may be effective in the 
treatment of SSc and started a double-blind study in patients with newly diag­
nosed SSc of which the results arc not yet published. Malaviya et al.(24), using the 
same treatment with slightly reduced doses in 11 patients, had to discontinue this 
treatment because of major toxicity in three patients, while six other patients 
showed minor side effects. The duration of their study was too short to assess any 
beneficial effect of 5-FU. 
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Methotrexate 
Welin et al.<25) treated two patients with SSc complicated by Sjogren's syndrome, 
with 25 mg methotrexate IV every two weeks up to a total dose of 275 and 350 
mg respectively. Both patients improved in range of motions of the fingers and 
one in softening of the skin of the dorsum of the hands. 
The same results were recently obtained by Van den Hoogen et al.(26), who treated 
one patient with weekly doses of 15 mg methotrexate intramusculary and one 
patient with 5 mg methotrexate orally (lower dose because of reduced renal 
function) and noted softening of the skin after 3 months of therapy; during the six 
months of their study no deterioration of renal function or other organ systems 
tested occurred. 
Cyclosporin 
Zachariae and Zachariae(27) noted impressive improvement of the sclerotic skin of 
the upper extremities and to a certain extent also of the skin of the trunk within 
four months of initiating cycloclosporin A (CyA) 7 mg/kg a day in a patient with 
diffuse SSc; they also found increased grip strength and lip-lip distance and 
decreased pulpar-volar distance in a patient with acrosclcrosis, treated with the 
same dose. 
Yocum and Wilder*2*' also noticed improvement of sclerotic skin six weeks after 
starting CyA therapy, 10 mg/kg daily in one patient with diffuse SSc and a 
marked increase in skin disease after discontinuation of the drug. After reinsti-
tution of CyA therapy gradual improvement reappeared. 
The most striking result of CyA therapy was reported by Appelboom and Itzko-
witch(2,), who treated one patient with pulmonary, cardiac and gastrointestinal 
manifestations with CyA (drug serum concentration was adjusted to 200 ng/ml 
during the entire treatment). Not only was dramatic diminution of skin abnor-
malities seen, but improvement of pulmonary function tests, echocardiography and 
barium swallow study also occurred. Anti-Scl-70 antibodies, demonstrable before 
the start of CyA therapy, were no longer detectable at the end. Progressive renal 
insufficiency developed, but this completely resolved within 4 weeks of 
discontinuation of CyA. 
Russell and Schachte^30' reported on treatment of 5 patients with SSc and one 
with morphea profundus with CyA. They found improvement in skin score and 
discomfort in 3 out of 4 patients who were treated for at least 6 months; two 
patients had permanent healing of severe skin ulcerations. After 8 months of 
treatment one patient developed renal failure typical of SSc, the other patients 
showed no deterioration of internal organ involvement during the study. 
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lnterferon-γ 
Recently Капал et al.(}l> published the results of a study in which they treated ten 
patients with recombinant intcrferon-γ (IFN-γ) once daily for seven days per 
week by intramuscular injections. The dosage of IFN-γ was gradually increased 
from 10 pg/day to 100 pg/day in one month and continued for another five 
months. One patient dropped out of the study after six weeks because of rapid 
worsening of the disease. The other nine patients showed a significant improve­
ment in total skin score, maximal oral opening, range of motions of wrists and 
elbows, grip strength, functional index, dysphagia and creatinine clearance. No 
serious side effects occurred. 
No drug with immunoregulatory activities has ever been shown to be effective in 
the treatment of SSc in an adequately controlled study. There are, however, pros­
pective uncontrolled studies and case reports that hint at a possible beneficial 
effect of some of these drugs, chiefly anti-metabolites (azathioprine, MTX and 5-
FU), cyclosporine and IFN-γ. In the absence of any drug available for the 
treatment of patients with SSc, these findings, even if uncontrolled, do justify 
clinical trials with these agents. Because of the extremely variable course of SSc 
these clinical trials ought to be placebo controlled in order to give a clearcut 
answer on the efficacy of the drug in the treatment of patients with SSc. The best 
SSc-patienis for study are those whose disease is of recent onset*32'; furthermore, 
the SSc-palients should be studied over a prolonged period of lime, preferably 
several years. In view of the positive results we obtained in a prospective study in 
which patients with SSc were treated with MTX(26), we recently started a double-
blind placebo-controlled study in which the efficacy of MTX in the treatment of 
SSc will be assessed. 
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Methotrexate treatment in systemic sclerosis 
A. Methotrexate treatment in scleroderma 
Many drugs have been used for (he treatment of scleroderma (systemic sclerosis, 
SSc), all without convincing evidence of efficacy'". We report the beneficial 
effect of methotrexate (MTX) therapy in two patients with SSc. 
Patient 1. 
A 67-year-old man had a two-year history of Raynaud's phenomenon, arthralgias 
and stiffness in both hands, and symmetric proximal muscle weakness. A diag-
nosis of overlap syndrome, consisting of SSc and polymyositis, was made based 
on sclerodactyly and scleroderma skin changes in both forearms and in the face, 
and typical electromyogram and muscle biopsy alterations with elevated serum 
creatine kinase values (maximum, 1900 U/L). Other symptoms included a dimin-
ution of peristaltic activity in the distal part of the oesophagus on cinefluoroscopic 
examination and complete left bundle branch block on the electrocardiogram. 
Autoantibodies to Scl-86(2) or Jo-1 antigen were not detectable. Treatment was 
started with weekly intramuscular injections of 15 mg of MTX. A gradual 
improvement of skin hardening was noted about three months after the beginning 
of therapy and continued for six months, when MTX had to be discontinued 
because of an aspergillosis lung infection. At that time, the scleroderma skin 
changes were only detectable in the fingers, the total skin score(3) was 8 compared 
with 22 at the starting point, and serum creatine kinase values had returned to 
normal. The lung infection was successfully treated with antibiotics. 
Patient 2. 
A 55-year-old woman had a two-year history of Raynaud's phenomenon and 
progressive scleroderma skin changes eventually covering the arms, legs, face and 
upper part of the thorax. Treatment with D-penicillamine had to be stopped 
because of severe side effects, and no improvement occurred with corticosteroid 
therapy (maximum, 15 mg/day). Instead, the scleroderma skin changes increased 
and an impairment of renal function developed (endogenous creatinine clearance 
of 45 mL/minute), accompanied by hypertension. Autoantibodies to Scl-86 antigen 
were not detectable. Treatment with MTX was commenced at a dosage of 5 
mg/day (dosage was lower than that in patient 1 because of impaired renal func-
tion) given orally; corticosteroid therapy was continued at a dosage of 7,5 milli-
grams/day and hypertension was controlled with nifedipine and hydrochloro-
thiazide. After three months of therapy, an improvement occurred in scleroderma 
skin changes and Raynaud's phenomenon; renal function showed no further 
deterioration. After six months of therapy, the total skin score was 22 as com-
pared to 41 at the beginning of therapy. No side effects of MTX were noted. 
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These observations suggest not only an effect of MTX on the progression of skin 
fibrosis, but also an improvement of already established skin fibrosis in patients 
with SSc. Our findings are in agreement with those previously reported by J. 
Welin et al<4), who also showed a softening of fibrotic skin in two patients with 
SSc receiving MTX therapy. However, the course of SSc is extremely variable 
and spontaneous improvement can occur; these observations therefore need to be 
confirmed in a controlled study. At this time, we are performing a double-blind 
trial of MTX and placebo in patients with SSc to assess the presumptive efficacy 
of MTX in SSc. 
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Chapter III 
В. Low Dose Methotrexate Treatment In Systemic Sclerosis 
Many drugs have been used in the treatment of patients with systemic sclerosis; 
however, no convincing evidence of efficacy of any of these drugs could be 
established'". Methotrexate (MTX) has been successfully applied in polymyosilis/-
dermatomyositis'2" and rheumatoid arthritis'4"6', diseases that display overlapping 
features with systemic sclerosis. 
We describe the results of a pilot study in which eight patients with systemic 
sclerosis according to the preliminary ARA criteria'7' were treated with MTX. The 
study lasted one year, and prior to the start of it all patients had active disease 
with either progression of skin fibrosis or persistent digital ulcerations. Four 
patients had previously been treated with D-pcnicillamine, but in all these patients 
this drug was stopped at least four months before the study because of lack of 
efficacy or side effects. Concurrent low dose prednisone therapy was continued in 
three patients. 
Treatment consisted of 15 mg MTX/week, given intramuscularly for the first six 
months and orally thereafter. One patient received a reduced dose of 5 mg 
MTX/week orally throughout the study because of impaired renal function. The 
demographic and clinical characteristics of (he patients arc listed in Table 1. 
Assessment at entry and after 6 and 12 months consisted of pulmonary function 
tests; chest, hand and feet radiographs, barium swallow of the oesophagus and 
electrocardiogram. During the first 6 months, patients' cases were evaluated every 
month, thereafter every two months. These evaluations included a detailed clinical 
examination performed by the same investigator and assessments of the degree 
and extension of skin fibrosis using the total skin score according to Steen'8'. Also 
measured were maximal oral opening and distance of the third fingertip to the 
most distal crease of the wrist with the fingers maximally extended (fingertip-
wrist distance). During each visit, blood samples were drawn for analysis of blood 
cell count, liver function tests, creatinine, creatine Phosphokinase, immuno­
globulins, complement levels and antitopoisomcrase-I antibodies, using a cloned 
topoisomerase protein as substrate in an ELISA'9'. Creatinine clearance was 
calculated using the Cockroft formula'10'. Student's t-test for continuous variables 
was used to calculate differences between baseline values and values recorded 
after 6 and 12 months. 
Seven patients completed the study. In one patient MTX was stopped after 6 
months because of pulmonary aspergillosis; the one-year evaluation of this patient 
is included in the overall results. Total skin score diminished from average 28.5 ± 
18.3 at baseline to 14 ± 10.5 (p<0.01) after one year (fig. 1). Skin softening was 
usually noted after 2 to 3 months of MTX therapy. Every patient had a reduction 
in total skin score of at least 25%. except for one patient, who experienced a 
rapid progression of skin fibrosis with cardiac, pulmonary and gastrointestinal 
involvement just prior to the start of the study. Maximal oral opening increased 
from average 39.1 ± 18.3 mm to 46.0 ± 9.4 mm (p<0.05). No significant change 
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occurred in fingertip-wrist distance, though a slight improvement was seen in five 
patients. Likewise, no significant changes occurred in the results of pulmonary 
function tests and chest radiographs nor were changes observed in cardiac 
conduction on electrocardiograms. In one patient, barium swallow revealed a 
diminished peristalsis of the oesophagus after 6 months that was not present at the 
beginning. Digital ulceration disappeared in three patients and markedly improved 
in one. From the start of the study there was a gradual though after 12 months 
significant, decrease of creatinine clearance; mean creatinine clearance fell from 
92.2 ml/min ± 29.5 to 85.4 ± 45.3 ml/min (p<0.05). The absence of other internal 
organ involvement suggests that this mild decrease in creatinine clearance may be 
caused primarily by MTX itself rather than by progression of renal sclerosis. Of 
all other serological variables tested, a reduction was found in circulating immune 
complexes from average 7.37 ± 3.54% to 2.25 ± 0.70% (p<0.01) after 12 months; 
IgM levels decreased from 2.06 ± 0.89 g/L to 1.69 ± 0.75 g/L (p<0.01) during the 
first 6 months of the study to remain steady thereafter, and C3-levcls increased 
from 1033 ± 227 g/L to 1303 ± 254 g/L (p<0.05) during the last 6 months of the 
study. The anti-topoisomerasc titers declined in all three positive patients. Whether 
these changes reflect a direct effect of MTX on the immune system or must be 
looked upon as secondary changes due to inactivation of the disease process 
cannot be elucidated from our data. 
Figure 1 Total skin score at study entry and after 6 and 12 months of low 
dose MTX treatment 
1 2 3 4 6 η 7 
petlente 
Entry V/Δ 0 mont he I 112 months 
In two patients, MTX therapy was temporarily withdrawn: one patient had a 
transient rise in transaminase values and the other patient had a herpes zoster 
infection of the 6ln cervical nerve. After restarting MTX no further complications 
were encountered. 
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Our data suggest a beneficial effect of MTX in the treatment of patients with 
systemic sclerosis with good tolerance of the drug. However, the short duration 
and the open design of the study preclude definite conclusions about any benefi-
cial effect of MTX in systemic sclerosis and a double-blind placebo controlled 
trial is urgently needed to confirm the results of this pilot study. Such a trial is 
currently being conducted in our department. 
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Methotrexate vs. placebo 
Summary 
Objective - To compare methotrexate with placebo in the treatment of systemic 
sclerosis in a 48 week, randomized, double-blind, placebo-controlled trial. 
Methods. Twenty-nine scleroderma patients were allocated to receive weekly 
injections of either 15 mg methotrexate or placebo. Patients who responded 
favorably after 24 weeks continued with the same regimen for a further 24 weeks; 
those who showed a poor response on placebo were allocated to further treatment 
with 15 mg methotrexate weekly, and those who responded poorly to treatment 
with 15 mg methotrexate weekly had their doses increased to 25 mg. Favorable 
response was defined as improvement of total skin score (TSS) by >30%, of single 
breath diffusion capacity (DLC0) by >15%, or of the score on a visual analogue 
scale of general well being (VAS) by >30Ψο, provided that such improvements 
were not accompanied by persistent digital ulcerations or worsening of DLC0 
>15%. 
Results - Seventeen patients were allocated to methotrexate treatment; 12 to 
treatment with placebo. Comparison between the two treatment groups at week 24 
showed improvement in the methotrexate group of TSS (p=0.06), VAS (p=0.17) 
and creatinine clearance (p=0.12). The number of withdrawals was two in both 
groups and due to renal crisis (n=2), progressive cardiopulmonary involvement 
(n=l) and severe headache (n=l). Breaking the code after 48 weeks of double-
blind treatment, it appeared that after 24 weeks a significant larger number of 
patients receiving methotrexate (n=8, 53Ψο) that completed the first 24 weeks of 
the study had responded favorably compared to patients receiving placebo (n=l, 
ΙΟΨο, p=0.03). At week 48, 13 patients received methotrexate from the start of the 
study and nine during 24 weeks. From these 22 patients, 15 (68%) responded 
favorably and compared with the start of the study they showed significant 
improvement of TSS (p=0.04), VAS (p=0.02), grip strength of right hand (p=0.02) 
and ESR (p=0.01). Two patients, both receiving an enhanced dose of 25 mg 
methotrexate died during the second 24-week period: one because of progressive 
disease and one presumably due to acute myocardial infarction. 
Conclusion - Low-dose methotrexate appears to be an effective treatment of 
systemic sclerosis. 
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Systemic sclerosis (SSc) or scleroderma is a multisystemic disease characterized 
by excessive deposition of collagen and other extracellular matrix components by 
Fibroblasts, damage to the endothelium of small vessels, resulting in intimai 
hyperplasia and tissue ischacmia, and activation of the immune system. These 
phenomena may lead to progressive fibrosis of the skin, muscles, joints, and 
internal organs, accounting for many of the clinical manifestations"·2'. The natural 
course of the disease may vary: a few patients experience spontaneous remission; 
the majority undergoes progression of skin and internal organ involvement, 
resulting in considerable morbidity and ultimately in death. Several studies have 
given estimates of five-year cumulative survival rates ranging from 34-73%l3). 
Male gender, older age, involvement of heart, lung or kidney, presence of 
antitopoisomerase I autoantibodies, and diffuse skin involvement adversely affect 
outcome'*45'. SSc is a rare disease, with an estimated annual incidence rate of 20 
new cases per million'7'. Its pathogenesis is unclear, but evidence suggests an 
autoimmune or vascular aetiology'8'. No treatment has proven convincingly to be 
effective. Several studies have reported favorable effects of certain drugs, but 
most of them consist of case reports, uncontrolled trials, or studies with historical 
controls " l5). Placebo-controlled, double-blind trials in SSc are scarce, and have 
given negative or inconclusive results"6"13'. 
Methotrexate (MTX) is an ani i folate drug. In low dosages it has shown favorable 
effects in the treatment of autoimmune diseases such as rheumatoid arthritis (RA) 
(24
'
a
' and dermato- and polymyositis'29,30'. We recently reported the results of a 
one-year pilot study in SSc patients treated with low-dose MTX. In the majority 
of the patients cutaneous symptoms improved within six months and no further 
internal organ deterioration was detected"". Similar encouraging observations 
have been reported in the meantime'32'. To obtain more data about the role of 
MTX in the treatment of SSc we conducted a double-blind trial comparing MTX 
and placebo, focussing on the efficacy and toxicity of these treatments and on the 
differences between rcspondcrs and nonresponders on MTX treatment. 
Patients and methods 
Patients 
The inclusion criteria for the trial consisted of the preliminary criteria for the 
classification of SSc of the American Rheumatism Association'33' and the require-
ment that disease duration from (he first signs of skin thickening was less than 
three years. Patients with longer disease duration were also included if they had 
experienced a progression of skin thickening, persistent digital ulcerations, or a 
deterioration in pulmonary function, during the last six months. All patients 
voluntarily signed an informed consent form; the study protocol was approved by 
the institution's ethical committee. 
We applied the following exclusion criteria: age less than 16 years; the presence 
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of another connective tissue disease or SSc-like illness related to exposure or 
ingestion; the presence of acute or chronic infection; pregnancy or childbearing 
potential without an acceptable means of contraception; the presence of liver 
disease, defined as a value exceeding twice the upper limit of normal for a hepatic 
function (est or the presence of a known liver disease; serum creatinine level >130 
pmol/1 or a creatinine clearance rate <50 ml/minute as estimated by the method of 
Cockcroft and Gaull(M); total lung capacity (TLC), vital lung capacity (VC), or 
single breath diffusion capacity for carbon monoxide (DL
co
) <50% of its pre­
dicted value; a leucocyte count of <3.5 χ lO'/liter or platelet count <150 χ 10'/-
liter; the presence of a concurrent neoplastic disease; the presence of insulin-
dependent diabetes mellitus; alcohol abuse (more than 4 oz/day); the use of an 
antifolate drug other than MTX such as sulfonamide dérivâtes, allopurinol or 
probenecid; and the presence of active peptic ulcer disease. 
Study design 
The study was set up as a mulliccnter single observer trial. Twenty-nine patients 
were enrolled between November 1989 and November 1991. Potentially disease-
modifying drugs, such as d-pcniciUaminc and colchicine, were discontinued at 
least three months prior to study entry. Patients were randomly allocated to 
treatment with cither MTX (Ledcrtrcxatc, Lederle Nederland bv. The Netherlands) 
or placebo, both of which were administered weekly by intramuscular injection. 
The weekly dose of MTX was initially 15 mg. The two groups were balanced for 
disease duration (lime between onset of skin thickening and entry to the trial) and 
extent of skin involvement, known prognostic factors for SSc. 
Since there is no consensus concerning the outcome measures to be used in 
assessing disease activity and, hence, response to treatment in SSc, we set up our 
own criteria by which response can be evaluated. We based them arbitrary on data 
from previous studies and on our own experience. They employ the following 
variables: total skin score (TSS), which is the sum of scores of 0-4 obtained 
manually at 26 anatomic locations, described by Steen et al.(9); visual analogue 
scale (VAS) of general well-being, as determined by the patient on a lOO-mm 
scale on which 100 mm represents optimal general well-being; lung diffusion 
capacity as reflected by DLco; and presence or absence of digital ulcerations. 
Response to treatment was defined as favorable if TSS or VAS improved by 
>30% or if DLC0 improved by >15%. However, when digital ulcerations devel-
oped or persisted or when DLro decreased by >15%, despite improvement of 
VAS or TSS, the response was defined as unfavorable. Evaluation of response 
criteria was performed double-blind at week 24 and 48. Patients with favorable 
response after 24 weeks of treatment continued the same regimen for another 24 
weeks. Nonresponders on placebo after 24 weeks were started on MTX 15 mg 
weekly; nonresponders on 15 mg MTX weekly received an increased dose of 25 
mg weekly for the remaining 24 weeks of the trial. The clinical examiner and the 
patients were blind regarding the changes in treatment; the treatment code was 
broken only after all patients had completed the 48 week study. All subjects were 
outpatients at the time of enrolment and were admitted to hospital during the 
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course of the study only in the event that severe complications occurred. 
Clinical assessment 
At study entry a detailed medical history was taken and the patient was given a 
thorough physical examination. Each patient was evaluated monthly during the 
trial year by the same investigator (FHJvdH). The evaluations consisted of: a 
detailed clinical examination and the determination of TSS, VAS, extension 
indices for both hands, grip strength in both hands, and maximal oral opening. An 
extension index is the distance between the tip of the third finger and the distal 
palmar crease with the hand fully extended. Grip strength was measured by a 
sphygmanometer (Tonometer, von Recklinghausen, Germany) with a range of 0-
300 mmHg; the value recorded was the maximum of three consecutive mea-
surements. At study entry and after 24 and 48 weeks of treatment, pulmonary 
function tests, including those for TLC, VC and DLC0 were performed, barium 
swallow of the oesophagus was measured, an electrocardiogram (ECG) was made, 
and a radiologic examination of the chest was performed. 
Laboratory assessment 
Haemoglobin level, white blood cell (WBC) and platelet counts, and hepatic and 
renal functions were evaluated weekly during the first month of treatment and 
then every four weeks for the remainder of the study. Hepatic function tests con-
sisted of the assessment of alkaline phosphatase, serum aspartate aminotransferase 
(AST), and serum alkaline aminotransferase (ALT) levels; renal function tests, of 
the assessment of serum creatinine and creatinine clearance rale according to the 
method of Cockcroft and Gault(34). Other laboratory variables measured once every 
four weeks from the beginning of therapy were: erythrocyte sedimentation rate 
(ESR) according to Wcstcrgren, serum levels of IgA, IgM, IgG, C3, C4 and 
circulating immune complexes and urinalysis. At study entry patients were tested 
for anlinuclear antibodies, by immunoblotting and counter Immunoelectrophoresis, 
and for rheumatoid factor, by the latex fixation lest. All laboratory tests except the 
hepatic and renal function tests and those for ESR and blood cell counts, were 
performed at the University Hospital Nijmegen, to ensure that uniform methods 
were used. 
Organ involvement 
Pulmonary dysfunction was defined as a VC and TLC <80% or DLco <70% of 
predicted normal values or chronic interstitial changes on chest roentgenograms; 
oesophageal dysfunction, as diminished motility as determined by barium swal-
low; cardiac dysfunction, as conduction disturbances on an ECG or cardiomegaly 
on a chest X-ray; renal dysfunction, as serum creatinine level >130 pmol/l or a 
creatinine clearance rate of <50 ml/minute as estimated according to the method 
of Cockcroft and Gault(34); and muscular involvement was defined as serum 
creatine Phosphokinase (CPK) level more than twice the upper limit of normal. 
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without proximal muscle weakness and without specific changes on an electro-
myogram. Muscle biopsies were not performed. SSc was considered diffuse if 
sclerotic skin changes were present proximal to the elbows or knees; SSc was 
considered limited if skin changes were present distal to the elbows or periorally 
with other areas being unaffected. 
Concurrent medication 
Concurrent treatment with corticosteroids at dosages not exceeding 10 mg/day, 
nonsteroidal anti-inflammatory drugs, analgesics, nifedipene, ketanserine, 
Cimetidine or Omeprazol was permitted. No changes in dosages were permitted 
from eight weeks before study entry until the end of the trial. 
Adverse reactions and withdrawals from the study 
At each visit patients were routinely questioned about symptoms related to MTX 
toxicity. The trial medication was temporarily withheld if the WBC count was less 
than 3.0 χ 10'/1, if the platelet count was less than 150 χ ÏO'/I, if liver enzyme 
levels exceeded three times the upper limit of normal, or if serum creatinine 
levels exceeded 160 pmol/l, for two consecutive measurements. Treatment was 
resumed once the values had normalized. If the same abnormality reoccurred a 
second time, after recovery the patients received a dose reduced by 50%. A third 
occurrence resulted in the patient's being permanently withdrawn from the study. 
Patients who failed to keep scheduled appointments at the clinic or whose clinical 
conditions deteriorated to such an extent as to necessitate other therapy were also 
permanently withdrawn. 
Statistical analysis 
Categorical variables were compared with Fisher's exact test. The Wilcoxon test 
was used to compare the changes in the variables over time in the MTX group 
with those in the placebo group. Ninety-five percent confidence intervals were 
calculated. For changes within the MTX group the sign rank test was used. 
Ρ values of 0.05 or less were considered significant. 
Results 
Patient characteristics 
Twenty-nine patients were enrolled in the study. Seventeen were allocated to 
MTX treatment; 12 to placebo treatment. This difference in numbers resulted 
from the fact that by mistake two patients in the MTX group were initially 
recorded as belonging to the placebo group. The error was discovered after 
breaking the code at the end of the study. Due to this error the number of patients 
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with diffuse and limited cutaneous involvement is also different, though not 
statistically significant, in both groups. Table 1 and the First column of Table 2 
give the initial demographic, clinical, and laboratory data of the two groups. The 
duration of cutaneous involvement, and the prevalence of Raynaud's phenomenon 
in the two groups were similar. Disease duration was less than one year for seven 
patients (41%) in the MTX group and four (33%) in the placebo group. Five 
patients receiving MTX (29%) and six patients receiving placebo (50%) were 
classified as having diffuse SSc. Digital ulcerations or pitting scars were present 
in 12 patients (70%) in the MTX group and in five (42%) in the placebo group. 
No autoantibodies other than antitopoisomerase I-, anti-centromere-, and anti-
RNP-antibodies and rheumatoid factor could be detected. CPK values were 
significantly higher (p=0.04) in the MTX group. Muscular involvement was 
somewhat more prevalent in the MTX group (p=0.10). There were no significant 
differences between the two groups with regard to internal organ involvement or 
previous treatment. 
Course of treatment 
The course of the trial is outlined in fig. 1. During the first 24 weeks of treatment 
two patients in each treatment group had to be withdrawn from the study (see 
further). After breaking the code at week 48, it appeared that eight (53%) of the 
15 patients in the MTX group who had completed the first 24 weeks had 
responded favorably after 24 weeks, whereas nine (90%) of the patients receiving 
placebo and completed the first 24 weeks did not respond favorably. This 
difference is significant: p=0.03. The favorable response among the patients 
receiving MTX was due to improvement in TSS in three cases, to improvement in 
VAS in four, and to improvement in both in one case. One patient whose VAS 
improved >30% was classified as nonresponder, owing to a >15% decrease in 
DLC0. The patient who responded while undergoing placebo treatment had >30% 
reduction in TSS. 
Two further patients, both of whom had been started on an increased dose of 25 
mg MTX weekly, had to be withdrawn between weeks 24 and 48 (see further), 
leaving 23 patients to complete the trial. At week 48, of the nine patients who had 
been transferred from placebo to MTX treatment after the first 24 weeks, five had 
responded favorably with >30% improvement in TSS. Two patients who had not 
responded to 15 mg MTX weekly during the first 24 weeks responded favorably 
to the increased dose of 25 mg with an improvement of >30% in VAS. Thus at 
week 48, of the 22 patients who had completed the trial and had been treated with 
MTX for at least 24 weeks, 15 (68%) responded favorably according to the 
predetermined criteria. 
Comparison of groups after 24 weeks 
The results of only those patients who completed the first 24 weeks of treatment 
were included in the analysis. Ten patients from the placebo group and 15 from 
the MTX group (fig. 1) were eligible. The differences between the initial and 
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Table 1: Patient characteristics at study entry* 
Va nable 
Age, mean t SD years (range) 
Duration of cutaneous SSc, 
mean 1 SD years (range) 
Sclerodermatous skin distribution 
diffuse 
limited 
Male 
Raynaud's phenomenon 
Duration of Raynaud's phenomenon 
mean ± SD years (range) 
Digital ulcers/scars 
Autoantibodies 
ANA 
Anti-TOPO 
Anticentromere 
Anti-RNP 
Rheumatoid factor 
Prevalence of organ involvement 
Pulmonary 
Cardiac 
Renal 
Oesophageal 
Muscular 
Previous treatments 
Penicillamine 
Prednisone 
NSAlD's 
Colchicine 
Methotrexate group 
(n-17) 
52 ± 12(32-75) 
3 2 ± 6 3 (0 1-27) 
5(29) 
12(71) 
7(41) 
17 (100) 
3 5 ± 7 0 (0 4-30) 
12 (70) 
15 (88) 
9(53) 
0 
1(6) 
5(29) 
9(53) 
3(18) 
0 
15 (88) 
5(29) 
6(35) 
3(18) 
5(29) 
1(6) 
Placebo group 
(n=12) 
56 ± 11 (39-72) 
3 2 ± 3 4 ( 0 6-12) 
6(50) 
6(50) 
2 (17/ 
11(92) 
5 6 ± 9 5 (0 9-34) 
5(42) 
11(91) 
7(58) 
1(9) 
0 
3(25) 
6(50) 
4(33) 
0 
10 (83) 
0» 
4(33) 
4(33) 
1(8) 
0 
* Values given are the number of patients and values in parentheses are percentages, unless otherwise indicated 
SSc-systemic sclerosis, ANA»antinuclear autoantibodies, RF=rheumatoid factor, 
anti-TOPO=antitopoisomerase I antibodies, anticentromere=anticentromcre antibodies, 
anli-RNP-anti-nbonucleoproleasc antibodies, 'p^> 32 and р^»Ю 10 for differences between groups 
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Methotrexate vs. placebo 
week-24 values of the clinical and laboratory variables are shown in Table 2 for 
both groups. After 24 weeks, the following differences in improvement of clinical 
variables between the MTX and placebo treated patients were found: 
a. TSS decreased by 0.7 in the MTX group and increased by 1.4 in the placebo 
group (p=0.06); 
b. VAS improved by 7.8 mm in the MTX group and remained approximately the 
same in the placebo group (p=0.17); 
с the creatinine clearance rate increased by 4.3 ml/min in the MTX group and 
decreased by 0.7 ml/min in the placebo group (p=0.12). 
The CPK values of two MTX patients reflecting pre-existing muscular involve­
ment decreased >50% and remained unchanged in two others. A fifth was with­
drawn from the study at week 10 due to renal crisis. One patient developed 
muscular involvement while undergoing MTX therapy. Differences between the 
groups with respect to laboratory variables consisted of a significantly greater 
decrease of haemoglobin level in the placebo group (p=0.04) and WBC count in 
the MTX group (p=0.003). IgM and IgG concentrations also decreased more in 
the MTX group, but not significantly (p=0.06 and p=0.08 respectively). 
Results after 48 weeks 
At the end of week 48, the treatment code was broken and it was found that only 
one patient was still being treated with placebo. Therefore, no comparison could 
be made between the placebo group and (he MTX group. Instead we compared 
the week-48 values with the initial values of the patients treated with MTX 
throughout the trial. The data of 13 patients were eligible for analysis, as two 
more had been withdrawn. Significant improvements were found in VAS (p=0.01) 
and grip strength of the right hand (p=0.04, Table 3), which was dominant in all 
patients. There was a tendency of improvement in TSS (p=0.12) and creatinine 
clearance rate (p=0.11). Other parameters concerning internal organs showed no 
change. Laboratory analysis demonstrated significant reductions in ESR (p=0.002), 
WBC count (p=0.04), thrombocyte count (p=0.04), and concentrations of IgM 
(p=0.0002) and IgG (p=0.0002). There were also minor decreases in the concen­
trations of C3 and CPK (p=0.08 and p=0.13 respectively) (Table 4). 
Responders versus nonresponders 
Of the 15 patients who could be classified as responders at the end of the trial, 
eight achieved a >30% improvement in TSS; six, a >30% improvement in VAS; 
and one, a >30% improvement in both. The initial values and the differences 
between the week 48 values and the initial values of clinical and laboratory 
variables of responders compared with those of nonresponders are shown in 
Tables 5a and 5b. The difference between the two groups regarding disease 
duration was due to the presence of two patients with longstanding disease among 
the responders, but was not significant. Significantly more women than men 
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Table 3: Clinical variables: differences with entry values after 48 weeks of treatment* 
Variable 
Total Skin Score 
Extension index right (mm) 
Extension index left (mm) 
Grip strength right (mm Hg) 
Gnp strength left (mm Hg) 
Oral opening (mm) 
General health (0-100mm VAS) 
Organ involvement 
Lung Fibrosis (N.%) 
TLC (% predicted) 
VC (% predicted) 
DLco 
Cardiac (N,%) 
Renal (N) 
Creatinine clearance rate (ml/min) 
Esophageal (N.%) 
Muscular (N,%) 
week 48 
MTX group 
(n=13) 
-2 0 (-5 6, 1 6) 
0 3 (-3 9, 4 5) 
0 6 (-3 2, 4 4) 
27 5 (-2 6, 57 7) 
7 5 (-19 4, 34 4) 
0 4 (-12,2 0) 
17 5 (1 9, 39 4) 
3(23) 
-1 09 (-3 4, 1 2) 
-0 9 (-4 8, 3 0) 
-0 04 (-0 14, 0 06) 
2(15) 
0 
3 5 (-13, 8 3) 
11 (85) 
2(15) 
p-value 
48 weeks baseline 
0 12 
0 26 
0 43 
004 
0 22 
0 30 
001 
10 
0 78 
066 
0 74 
10 
Oil 
10 
0 40 
* Values in parentheses are 95% confidence intervals unless otherwise indicated MTX = methotrexate, 
VAS = visual analogue scale, TLC = total lung capacity, VC = vital capacity, 
DLfo = diffusion capacity for carbon monoxide See text for definitions of organ involvement 
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Table 4: Laboratory variables: differences with entry values after 48 weeks 
of treatment* 
Variable 
Creatine Phosphokinase (U/ml) 
ESR (Westergren, mm/h) 
Haemoglobin (mmol/1) 
WBC (хЮ'Л) 
Thrombocytes (xlO'/l) 
IgA (gl\) 
IgM (g/1) 
IgG(g/l) 
C3 (т
в
Л) 
C4 (rngfl) 
Ci re immune complexes (%) 
week 48 
MTX group 
(n=13) 
-51.0 (-134.5. 32.5) 
-8.2 (-14.0, -2.4) 
-0.1 (-0.3,0.1) 
-0.6 (-1.9,0.7) 
-46 (-95, 2.9) 
0.09 (-0.5. 0.7) 
-0.32 (-0.45, -0.19) 
-1.94 (-3.0,-0.9) 
-82 (-207, 43.1) 
-18 (-62.26) 
1.67 (-0.08. 3.42) 
p-value 
48 weeks-baseline 
0.13 
0.001 
0.75 
0.87 
0.04 
0.79 
0.0002 
0.0002 
0.08 
0.27 
0.98 
1
 Values in parentheses are 95% confidence intervals. 
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responded favorably (p=0.05). Antitopoisomerase I antibodies seemed to be 
identified more frequently in the nonresponders (p=0.06) and mean C4 levels were 
significantly higher at study entry in the responders. There were no further 
differences between responders and nonresponders with respect to any of the other 
variables that were tested at study entry. 
By week 48 the responders showed significant improvement in TSS (p=0.04), grip 
strength of the (dominant) right hand (p=0.02), and VAS (p=0.02). There was also 
some improvement in the grip strength of the left hand (p=0.09). DLC0 decreased 
slightly (p=0.12), and VC and TLC remained unchanged. Mean ESR, haemoglo-
bin concentration, and thrombocyte count dropped significantly (p=0.01, p=0.003 
and p=0.05 respectively). Likewise, mean IgG and C3 levels dropped significantly 
(p=0.003 and p=0.005 respectively). Among nonresponders, the extension indices 
of the right and left hand worsened significantly (p=0.05 and p=0.02 respectively), 
as did TLC (p=0.02) and VC (p=0.01), and mean IgA increased significantly 
(p=0.04). 
Diffuse and limited skin involvement, short and long disease duration 
There were no significant differences between the changes that occurred among 
patients with diffuse skin involvement and those that occurred among patients 
with limited skin involvement or between the changes that occurred among 
patients with disease duration of more than one year and those that occurred 
among patients with disease duration of less than one year (data not shown). 
Withdrawals and adverse reactions 
Withdrawals and adverse reactions are summarized in Table 6. One patient from 
the placebo group experienced a severe progression of cardiopulmonary and 
gastrointestinal manifestations of SSc, eventually accompanied by a renal crisis of 
which she died in week 10. Another patient receiving placebo had to be with-
drawn in week 12, owing to renal failure due to scleroderma renal crisis. Two 
patients from the MTX group were also withdrawn: one in week 10 because of 
renal failure due to scleroderma renal crisis, which was successfully treated in the 
acute phase, but which left the patient with chronic renal failure; another because 
she suffered from persistent, severe headache after each injection. Two patients 
died between weeks 24 and 48: one patient died because of cardiorespiratory 
insufficiency caused by progressive pulmonary fibrosis; the other died suddenly 
presumably because of acute myocardial infarction. Both patients had been 
receiving an increased dose of 25 mg MTX weekly. The patient who died of 
cardiorespiratory insufficiency had suffered shortly before from a pancytopenia. 
This pancytopenia had completely recovered after temporary withholding MTX. 
Six patients receiving MTX experienced liver enzyme abnormalities characterized 
by elevated levels of AST and ALT. These normalized in two to four weeks after 
the trial medication had been withheld. None of these patients experienced 
recurrences of hepatic function abnormalities after resuming MTX. None of the 
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patients in the placebo group experienced any adverse reaction that could be 
ascribed to the injections. 
Discussion 
The design of this study was largely determined by the findings of our pilot study 
(31)
, in which skin thickening was reversed within six months of the beginning of 
MTX therapy. It was therefore felt that, because of the seriousness of SSc, a 
potentially beneficial treatment could not be withheld from patients in a placebo 
group for more than six months. In a recent editorial it was recommended that 
therapeutic trials among scleroderma patients should last at least two years, 
because of the variability of the course of the disease135'. However, the same 
authors concluded later that the best period for evaluating therapies that are 
intended to affect skin thickening is probably the first year of treatment'3*'. 
The rarity of SSc limits the number of patients available for trials, unless multi-
center trials are undertaken. Multiobservcr examinations, on the other hand, are 
liable to diminish the reliability of TSS, which is the most important marker of 
disease progress. We chose for one observer in this multicentre trial as TSS is at 
least as reliable in SSc as joint count in rheumatoid arthritis, provided that it is 
evaluated serially by a single investigator*37'. 
The paucity of suitable disease variables makes it difficult to evaluate therapies 
for SSc. It was necessary to develop criteria for separating responders and 
nonrespondcrs. These employed a combination of TSS, VAS, DLC0, and the 
presence or absence of digital ulcers. The choice was based on findings reported 
in the literature and our own experience. Pope and Bellamy recently reviewed the 
literature dealing with outcome measurements for treatments of scleroderma 
patients in clinical trials'38'. They too concluded that skin score measurements and 
global assessment arc the best primary outcome measures for clinical trials; good 
secondary measures include variables of internal organ involvement, mortality, 
functional assessment, and physical parameters such as grip strength and extension 
index. After 24 weeks of treatment there was a trend for improvement in the 
MTX group for the disease activity variables TSS and VAS. Analysis of results at 
week 48 between the two groups could not be made since at week 24 all placebo 
treated patients except one were switched to MTX treatment according to the 
study protocol. Analysis of MTX treated patients at week 48 showed that 68% of 
the patients in the present study benefitted from MTX treatment: skin scores and 
global assessment improved in a significantly larger proportion of the MTX group 
than of the placebo group. 
Low-dose MTX is suspected of impairing renal function, principally glomerular 
and tubular function, especially when it is used in combination with other 
nephrotoxic drugs'3'·40'. We found no reduction in renal function as measured by 
creatinine clearance rate as we observed in the pilot study. This may have been 
because only a few patients in the present study used potentially nephrotoxic 
drugs (nonsteroidal anti-inflammatory drugs or Cimetidine in a constant dose). 
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Only one patient had to be permanently withdrawn from the study because of side 
effects (severe headache) attributable to MTX. MTX would therefore appear to be 
reasonably well tolerated and safe in low, weekly, intramuscular dosages. The 
number of adverse reactions was relatively high, but in general minor and 
manageable. The occurrence of transient hepatic function disturbances in six 
patients and pancytopenia in one emphasizes the necessity of closely monitoring 
hepatic function tests and blood cell counts. 
Elevated ESR and thrombocyte count are associated with inflammation. The 
significant decrease in both variables after 48 weeks of treatment with MTX may 
reflect a reduction in the inflammatory process. The same may be true of the 
decrease in IgM and IgG concentrations, although this may also be due to direct 
inhibition of B-cell activity by MTX. Such an anti-inflammatory effect has been 
hypothesized as the mechanism through which MTX acts in rheumatoid arthritis, 
because of rapid clinical response to treatment and equally rapid flare-up upon 
discontinuation'4". Somewhat similarly we observed severe and rapid progression 
of cutaneous and internal organ involvement in two patients six weeks after MTX 
had been withheld. One of these patients is described in detail elsewhere<42). 
The mechanism through which MTX acts in SSc has yet to be established. Direct 
inhibition of extracellular matrix production by fibroblasts is unlikely: we recently 
reported that MTX, unexpectedly, did not reduce but even enhance glycosamino-
glycan production by scleroderma fibroblasts in culture'43'. 
More patients whose serum was positive for antitopoisomerase I antibodies and 
significantly more patients of male gender failed to respond to MTX therapy. 
Both variables are known to be associated with an unfavorable prognosis in SSc. 
The dosage of 15 mg MTX weekly seemed to be sufficient for the majority of 
patients who responded favorably. A higher dose of 25 mg may be necessary in 
those cases in which it is not. 
This study demonstrates that 68% of SSc patients respond favorably to MTX 
therapy with reductions in skin thickness or improvements in general well-being 
and without further damage to internal organs after 48 weeks. Long-term prospec­
tive trials examining efficacy and toxicity and randomized trials comparing MTX 
with, for example, d-penicillamine or cyclosporine will determine the position of 
MTX therapy in the treatment of scleroderma. 
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Effects of MTX on Glycosaminoglycanproduction 
Summary 
Objective - To determine the effects of increasing concentrations of methotrexate 
on the proliferation and glycosaminoglycan (GAG) synthesis of cultured dermal 
fibroblasts from patients with scleroderma. 
Methods - Cultured dermal fibroblasts from nine patients with scleroderma and 
nine normal volunteers were grown for 72 hours in media containing various 
concentrations of methotrexate. The GAG synthesis in each cell was measured 
after incubating the fibroblasts with [3H]glucosamine and [3SS]sulfate. 
Results - A negative correlation was found between the concentration of 
methotrexate and numbers of fibroblasts from patients with scleroderma and 
normal controls. A positive correlation was found between GAG synthesis in each 
cell, as measured by [3H]glucosamine and [}5S]sulfate incorporation, and increas-
ing methotrexate concentrations in fibroblasts from patients with scleroderma and 
normal controls. 
Conclusions - These data indicate increased GAG synthesis in scleroderma and 
normal fibroblasts with increasing concentrations of methotrexate. Therefore the 
reported beneficial effect of methotrexate on skin fibrosis in scleroderma is most 
probably not the result of direct inhibition of GAG synthesis by fibroblasts. 
Introduction 
Systemic sclerosis (SSc) is characterized by proliferative vascular lesions, chronic 
inflammatory infiltrations, and an excessive accumulation of connective tissue in 
many organs. Abnormalities in the functioning of the fibroblasts are considered to 
be responsible for progressive fibrosis in SSc. Tissue cultures of dermal fibro-
blasts from SSc patients have been found to synthesize collagen at an increased 
rate(1,2) and to accumulate up to five times more glycosaminoglycans (GAGs) than 
normal skin fibroblasts'3,4'. There is evidence to suggest that most of the increase 
in GAG synthesis is in the hyaluronic acid fraction'3·4'. 
Methotrexate (MTX) in low doses is efficacious in treating several connective 
tissue diseases, such as rheumatoid arthritis (RA)'5,6', dermatomyositis and poly-
myositis'7'. Low doses MTX have also been reported to reduce skin thickening in 
patients with SSc'8". The mechanisms through which low doses MTX affects the 
inflammatory process in rheumatic disease are as yet unknown. Most studies of 
immune system in RA patients who have been treated with low-dose MTX show 
only marginal effects on humoral and cellular immune responses. The rapid 
clinical responses to treatment and equally rapid flare up upon discontinuation 
suggest an anti-inflammatory effect'10'. One study suggests that one of the roles of 
MTX in RA may be to inhibit interleukin-1 mediated proliferation of synovial 
fibroblasts"". 
This study was undertaken to determine the effects of increasing concentrations of 
MTX on the proliferation of cultured scleroderma skin fibroblasts and their 
production of GAGs. 
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Patients and methods 
Patients with scleroderma and normal volunteers 
The nine patients fulfilled (he American Rheumatism Association's preliminary 
criteria for the diagnosis of SSc(12). The mean (SD) age of the patients was 49.4 
(8.4) years, with a range of 38 to 63 years. Seven patients were women and two 
were men. Five had diffuse SSc - that is, with the skin proximal to the elbows 
affected - and four had limited SSc - that is, with the skin distal to the elbows 
affected. Disease duration, estimated from the first signs of skin thickening, varied 
from six months to seven years, the median being 48 months. In six patients 
antibodies to topoisomerase I could be detected; in two others anticentromere 
antibodies were found. None of the patients had previously received any drug 
treatment known to influence connective tissue metabolism. The control group 
consisted of nine normal volunteers, five men and four women, with a mean (SD) 
age of 46.4 (11.7) years (range 29-67 years). 
Fibroblast expiant cultures 
Full thickness skin biopsy samples were taken with a 4 mm punch from each 
patient at a site of dermal thickening on (he dorsum of the left forearm; from each 
donor a biopsy sample was taken from either the dorsal forearm or the upper arm. 
Each biopsy specimen was minced and placed in a 25 cm2 plastic (issue culture 
flask (Costar, Cambridge, MA, USA), (o which 4 ml nutrient medium was added. 
The latter consisted of Dulbecco's modified Eagle's medium (DMEM; Flow 
Laboratories, Irvine, Stralhclyde, UK) that contained 0.002 M glutamine and 0.02 
M HEPES buffer and had been supplemented with 15% fetal calf serum and 
gentamicin (40 pg/ml, Schering, Kenilworth, NJ, USA). In addition to Hepes 
buffer the medium pH was controlled by sodium hydrogencarbonate. Each culture 
was maintained at 37°C in a humidified atmosphere of a C0 2 incubator containing 
5% C0 2 in air. The medium was completely replaced one to three limes a week, 
depending on the change in color. Once fibroblasts had grown from an expiant 
culture, (he old medium was discarded and fibroblasts were dispersed with 1 ml 
0.05% trypsin (Sigma Chemical Co., St. Louis, MO, USA) for 15 minutes at 
37°C. The cells were left in the same flask and 4 ml of nutrient medium was 
added. When they reached confluence, the fibroblasts were trypsinized again and 
divided equally between two 25 cm2 tissue culture flasks to each of which 4 ml of 
nutrient medium was added. When these cell layers had become confluent, they 
were trypsinized once more and the dispersed fibroblasts of each subculture were 
divided equally among 20 wells of one of two identical 24-well tissue culture 
plates (Costar). A 500 μΙ volume of nutrient medium was added to each of these 
40 wells. After 24 hours this was completely replaced with 500 μΐ fresh medium 
containing MTX in a concentration of 0, IO"", IO"6, 10" or IO'2 mol/1. Each of the 
five concentrations was assigned to four wells on each plate. These cultures were 
then further incubated under the conditions described. All subsequent determina-
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tions were performed on the contents of the quadruplicate wells. 
Measurement of GAG synthesis 
The fibroblast cultures of one tissue culture plate were labeled with 185 kBq 
[JH]glucosamine (NEN Products, Dupont, Boston, MA, USA) and 185 kBq 
[35S]sulfate (NEN Products) in each well, three days after the MTX had been 
added. The next day, all medium was decanted from each well and supplemented 
with 200 μΐ papain (1 mg/ml; Sigma Chemical). The fibroblasts were trypsinized 
(200 μΐ/well) and mixed with 100 μΐ papain (5 mg/ml). The cells and decanted 
media were incubated at 60°C for 24 hours. A 0.2% solution of celylpyridinium 
chloride (CPC) was then added, 400 ul to fibroblasts and 600 μΐ to medium, to 
obtain a final concentration of 0.1% in all samples. These were incubated at 37°C 
for one hour to allow the GAG-CPC complex to precipitate. The resulting pellets 
were centrifuged and washed, the cell fraction twice and medium fraction three 
times, with CPC 0.05% to remove any remaining glycopeptides and unincorpor­
ated precursors. Each pellet was then supplemented with 0.5 ml Luma solve 
(Lumac.LSC BV, Olen, Belgium) and, after an incubation of 10 minutes at 60°C, 
10 ml Lipoluma (Lumac.LSC) was added. The [3H]glucosamine and [35S]sulfate 
content of the pellets was determined in a liquid scintillation counter (LKB, 
Sweden), and appropriate corrections for the [3H]-[35S] overlap were made. As 
these experiments were not performed simultaneously, the specific activities of the 
isotopes had been determined before labeling. The results were corrected for the 
decrease in radioactivity that occurred during the course of the study to obtain 
figures for the levels of incorporation that could be compared. 
Fibroblast count 
The second tissue culture plate was used for counting cells. Four days after MTX 
had been added to the cultures, the media were decanted. The cells were washed 
twice with 400 μΐ phosphate buffered saline per well. Following trypsinization 
(200 μΐ/well), the cells of each well were counted with a Biirker hemocytometcr. 
The [3H] and [35S] counts/minute (cpm) of each of the quadruplicate cultures were 
divided by the corresponding number of cells to obtain the GAG synthesis for 
each fibroblast, to eliminate the effect of MTX on cell proliferation. 
Statistical analysis 
For all of the variables the means were calculated for quadruplicate cultures. 
Comparisons between groups were performed with the two tailed Wilcoxon (est. 
Spearman rank correlation coefficients were calculated, and Fisher's Ζ method 
applied, ρ Values of 0.01 or less were considered significant. 
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Results 
Fibroblast proliferation 
As shown in fig. 1, the mean number of cells was significantly inversely related 
to the concentration of MTX to which they had been exposed. The mean number 
of scleroderma fibroblasts in each well was lower than that of control fibroblasts 
for all concentrations of MTX except 1 χ IO"2 mol/1, but the differences were not 
significant. 
Figure 1 Mean cell number per well of patients and controls at different 
methotrexate (MTX) concentrations 
cell number (X1000) 
260 η 
2 0 0 -
1Б0-
100-
6 0 -
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Effect of methotrexate on fibroblast proliferation. Methotrexate causes a 
dose-dependent decrease of scleroderma (P<0.001) and normal (P<0.001) 
fibroblast numbers. No differences were observed between the numbers of 
scleroderma and normal fibroblasts. 
GAG synthesis 
There was a positive correlation between the total amount of [3H] (mean [3H] 
count rate in cells plus mean [3H] count rate in media of quadruplicate cultures) 
and the corresponding concentration of MTX for scleroderma and normal 
fibroblasts (fig. 2a). Likewise, total [35S] count rate was positively correlated with 
the corresponding concentration of MTX (fig. 2b). 
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Figure 2a Total 3H counts of scleroderma and control fibroblasts 
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Figure 2b Total "S counts of scleroderma and control fibroblasts 
Cpm/oell 
60 
40 
SO 
20 
10 
MTX о 
(mol/L) 
10 ' 
I SEM — ~ 
1 0 * 
petlente 
10 
- controle 
10' 
Mean total [3H] (fig. 2a) and [35S] (fig. 2b) counts per minute (cpm) per cell of 
scleroderma and normal fibroblasts. Each value represents the mean and 
SEM of quadruplicate cultures. A positive correlation was found between the 
concentration of methotrexate and both total [3H] cpm of scleroderma 
(P<0.001) and normal (P<0.001) fibroblasts and total [35S] cpm of scleroder­
ma (P<0.001) and normal (P<0.001) fibroblasts. An asterisk indicates a 
significant difference (P<0.01). 
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As the extent of skin disease and disease duration in SSc may influence GAG 
synthesis, we compared the results for Fibroblast cultures derived from specimens 
from five patients with diffuse skin disease with those for cultures derived from 
specimens from four patients with limited skin disease. For each concentration of 
MTX the total [3H] and [35S] count rates were higher for diffuse disease 
fibroblasts than for limited disease fibroblasts (p<0.01). There was no difference 
between the total [3H] or [35S] cpm of limited disease fibroblasts and those of 
normal Fibroblasts. 
The results for fibroblast cultures derived from specimens from five patients with 
a disease duration of more than three years were compared with those derived 
from specimens from four patients with a disease duration of less than three 
years. The total [3H] and [35S] count rates were higher for patient with long term 
disease than for those with short term disease, but the differences were significant 
for a MTX concentration 1 χ IO"4 mol/1 only. Values of total [3H] and [35S] count 
rates of normal fibroblasts were between the values of Fibroblasts of patients with 
long term and short term disease and were not significantly different from either 
of these. 
More than half the newly synthesized GAGs were secreted into the media (Table 
1). Scleroderma and normal fibroblasts secreted a higher percentage of [3H]-
glucosamine labeled GAGs into the media than [35S]sulfate labeled GAGs 
(p<0.001). 
Discussion 
MTX has been reported to be efficacious in the treatment of SSc and particularly 
in treating the affected skinlW). If the beneficial effect of MTX is a result of it 
acting directly on the fibroblasts, this might be either by inhibiting their prolifer­
ation or by decreasing the production of extracellular matrix. MTX, an antagonist 
of folate dependent enzymes, interferes with de novo pyrimidine and purine 
synthesis of RNA and DNA and, hence, blocks cell proliferation. The inverse 
relation between the number of cells and MTX concentrations in scleroderma and 
normal Fibroblasts was therefore to be expected. The proliferation rate was 
approximately the same in scleroderma and normal Fibroblasts. 
Total [3H] and total [3SS] count rates were positively correlated with the concen­
tration of MTX for scleroderma and normal fibroblasts. As total [3H] and [35S] 
count rates reflect the incorporation of [3H]glucosamine and [35S]sulfate into 
GAGs, these results show that, in scleroderma and normal Fibroblast cultures, 
GAG synthesis increases with increasing concentrations of MTX. 
Production of GAGs by scleroderma fibroblasts as measured by the total [3H] 
count rate was significantly greater than that by normal Fibroblasts for all concen­
trations of MTX. The production of GAGs as measured by total [35S] count rate 
was significantly greater in scleroderma Fibroblasts in the absence of MTX and at 
concentrations of 1 χ 10 e and 1 χ IO6 mol/1. As [3H]glucosamine is incorporated 
into all GAGs, and [35S]sulfate into sulfate containing GAGs only, thus leaving 
68 
Effects of MTX on Glycosaminoglycanproduction 
те 
E 
о» 
<r> 
+1 
c i 
00 
г-
•H 
о 
00 
Ή 
-Η 
es 
— 
-Η 
es 
E a. 
о, 
ai 
S 
с 
1 
к— 
s. 
•ί 
о 
r~ 
•H 
0 0 
o\ 
•H 
Г -
- H 
•H 
о 
VO 
>-i 
-H 
ь 
t ~ 
-H 
i n 
r-
-H 
•4-
0 0 
-H 
es 
-H 
VO 
1 Л 
о 
υ 
w 
** 
C0 
Г 
0 0 
-H 
VO 
0 0 
-H 
r-
r-
•H 
es 
VO 
es 
ι—ι 
•H 
0 0 
ΙΛ1 
£ со 
Ε Ξ 
ss 
о ¡S 
F* 
*2— С 
0 0 
Ή 
О 
00 
VO 
-Η 
— 
-Η 
VO 
ο\ 
•Η 
1 Л 
«ο 
α> 
со 
s-« 
Иг 
£ = 
s ° 
S ο « 2 
со 
Ο 
ε, 
с 
ο 
'£ 
Ь 
с 
о 
с 
о 
E 
s 
із E 
E 
Q 
О 
Χ (^  
01 
5 
С 
§ 
СЛ 
ι 
з 2 
Χι 
<ΐ 
я 
Ι 
•ο 
ο 1 
С/5 
Μ 
LO 
ІЗ 2 
ο 
μ* χ>
•a 
g 
о 
ζ 
E 
Э 
••§ 
ε 
E 
в 
о 
й (^  
tu 
61 
с 
<-> 
§ 
С/3 
1 
X I 
2 X I 
1 С 
сч i 4> 
"8 
Ім 
— 
00 
Vi 
з 
я 
χ 
2 
χ 
і м 
•a 
g 
о 
Chapter V 
hyaluronic acid unlabeled by [35S]sulfate, this indicates an enhanced accumulation 
of hyaluronic acid in scleroderma fibroblasts at higher MTX concentrations. The 
possibility that undersulphated GAGs are produced cannot be totally excluded, 
however. 
As diffuse skin disease was associated with a greater production of GAGs than 
limited skin disease which was associated with a level of production similar to 
that of normal fibroblasts, the increased production of GAGs by scleroderma 
fibroblasts must be attributed primarily to those derived from the biopsy speci-
mens from patients with diffuse skin disease. 
SSc is believed to be at its most active during the first three years. We had, 
therefore, expected a greater production of GAG to be associated with short 
disease duration than with long disease duration. We found, however, a greater 
production of GAGs in fibroblast cultures of patients with long term disease. The 
difference was not significant, perhaps because the number of patients was too 
small. 
The concentration of MTX had no effect on the percentages of newly synthesized 
[J5S]sulfate or [3H]glucosamine labeled GAGs that were secreted into the media 
by the scleroderma fibroblasts, which were comparable with those found by 
Bashey et al.w. This shows that MTX does not cause a shift in the distribution of 
GAGs between the cells and medium. 
Considering the mechanisms through which MTX is known to act, we had 
expected GAG synthesis to decrease as the concentration of MTX increased. The 
results show, however, that GAG production by cultured fibroblasts, whether 
scleroderma or normal, actually increases with increasing MTX concentrations. 
There are several possible explanations for this. First, the synthesis of extracel-
lular matrix may be suppressed through contact inhibition (l3>. As shown in fig 1, 
MTX reduces the number, and therefore the density, of fibroblasts as its concen-
tration increases, thus creating a population in which less contact inhibition can 
occur. This could lead to more GAG synthesis for each fibroblast. 
Second, MTX may have been responsible for selecting those fibroblasts with high 
rates of GAG synthesis. It has been established that normal and scleroderma 
fibroblasts are heterogeneous with respect to their synthetic and proliferative 
capabilities and that SSc fibroblasts are somehow selected so that high producers 
of connective tissue are favored at the expense of low producers, which they 
replace"4'. Third, the increase in GAG synthesis may be due primarily to 
decreased degradation, as a result of the interference by MTX with the synthesis 
of GAG degrading enzymes, rather than to increased production. Finally, by 
blocking DNA synthesis and thus cell proliferation, MTX may promote a 
fibroblast differentiation that is accompanied by protein synthesis. MTX has been 
reported to induce differentiation of cultured human keratinocytes, resulting in an 
increase in protein synthesis by a factor of 2 - 2.3(15). 
The results obtained in this study are inconsistent with the reported beneficial 
effect of low doses of MTX on sclerosis of the skin in SSc. Therefore any benefi-
cial effect of MTX on skin thickening in SSc is most probably not the result of 
direct inhibition of GAG production by fibroblasts, but is more likely to be based 
on modulation of the (immuno)inflammatory system. 
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A recombinant topoisomerase for autoantibody detection 
Summary 
We report the expression of a cDNA clone encoding 695 carboxyl-terminal amino 
acids of human DNA topoisomerase I (topoi) in Escherichia coli. More than 969o 
of the anti-HeLa topoi -positive sera from patients with a connective tissue disease 
displayed also an immunoreactivity with this recombinant protein (the HTopoA 
protein). Sera from patients with a definite diagnosis systemic sclerosis and 
reacting with HeLa topol, all reacted with the HTopoA protein as well. Sera from 
patients with systemic sclerosis that did not contain anti-topol antibodies (about 
30% of the systemic sclerosis sera), as concluded from HeLa immunoblot, 
displayed also no immunoreactivity with our recombinant antigen. By expressing 
different fragments of HTopoA, we were able to assign at least three different 
autoimmune epitope regions on the HTopoA protein and we show that over a 
period of 5 years the amount of anti-topol antibodies against these regions may 
fluctuate. 
Introduction 
In the eukaryotic cell, the topological states of DNA are modulated by two 
enzymes known as type I and type II DNA topoisomerase. The type I enzyme 
(topoisomerase I; topol) interconverts different topological forms of DNA by 
creating a transient single-stranded nick in the DNA backbone, passing the 
unbroken strand of the DNA through the nick, and resealing the original 
scission"·2'. Although topol is not necessary for the viability of eukaryotic cells'3,4', 
it docs appear to play important roles in chromatic organization'4', mitosis<5), DNA 
replication'6,7', recombination'8·" and transcription'10·11'. 
Autoantibodies directed against DNA topoi in sera of patients with systemic 
sclerosis have been described by several investigators'12"18'. These autoantibodies 
are usually detected by the immunodiffusion or by the more sensitive immuno-
blotling technique"8'. Thymus extracts'18' and HeLa cell extracts'5' are the most 
widely used antigen sources in these tests. In the present study we report the 
expression of a cDNA clone encoding 695 carboxyl-terminal amino acids (=91%) 
of human topol. The DNA sequence of this clone is identical with nucleotides 
418-3409 of the earlier described topol clone TIB"9'. Our recombinant topol 
protein (HTopoA protein) displayed an immunoreactivity with 82 of 85 anti-topol-
positive sera (=96%) indicating the usefulness of the HTopoA protein in routine 
detection of anti-topol antibodies in sera from patients with connective tissue 
diseases. 
Furthermore, we were able to assign at least three different autoimmune epitope 
regions on the HTopoA protein and show that over a period of 5 years the 
amount of anti-topol antibodies against these regions may fluctuate. 
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Materials and methods 
Sera 
Most patient sera were obtained from the Department of Rheumatology of the 
University Hospital St Radboud at Nijmegen, The Netherlands. Some additional 
sera were received from hospitals in Enschede, Deventer and Groningen, the 
Netherlands. 
Cells 
Culturing of HeLa S3 suspension cells as well as preparation of HeLa total 
nuclear protein fraction has been described*214. 
Bacteria and growth media 
Escherichia coli strains Y1089 and RR1 were purchased from Promega Biotec 
(Madison, WI). The strains HMS174 and BL21 (DE3) were provided by Dr F.W. 
Studier (Brookhaven National Laboratory, NY) and grown as described'21,22). 
When growing phage- or plasmid-containing cells, ampicillin (Sigma) was added 
to the medium at a final concentration of 100 pg/ml. 
Screening of a Xgt11 expression library with antibody probes 
A systemic sclerosis serum (diluted 1/500) with a high titre of anti-topol anti­
bodies was used to screen a human placental cDNA library (Clontech) constructed 
with the Xgll 1 vector as described previously<23). To detect specifically bound 
antibody, 125I-labelled sheep anti-human immunoglobulin F(ab)2 fragment 
(Amersham) was used. 
Expression of topol as fusion proteins 
The clone λΗΤοροΒ (see Results) was transferred to the lysogenic host E. coli 
Y1089. The lysogen was induced by temperature shift and addition of 10 mM 
isopropyl-ß-D-thiogalactopyranoside (IPTG) allowing maximal fusion protein 
synthesis'24'. 
The cDNA HTopoA (see Results) was inserted into the ВатШ site of the pET-3c 
expression vector*21,22) to yield pEHTopoA. E. coli HMS174 was used as host 
strain for initial cloning of the target DNA into the pET vector and for maintain­
ing the plasmids. E. coli BL21(DE3) was used as host for expression of 
pEHTopoA. BL21(DE3) contains a single copy of the gene for T7 RNA polyme­
rase in the chromosome under control of the inducible /arUV5 promotor. Tran­
scription of pET-3c is controlled by the strong φ 10 promotor for 17 RNA 
polymerase. Addition of 0-4 mM IPTG to a growing culture of BL21(DE3)/pEH-
TopoA induces T7 RNa polymerase, which in tum transcribes HTopoA in the 
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pET-3c plasm id. 
In this study we also used a topoi cDNA clone which was isolated from a HeLa 
cell DNA library'251. The isolated clone, referred to as the A-sequcnce, contains an 
insert of 2177 bp, corresponding to nucleotides 1241-3425 of the sequence 
published by D'Arpa et al.(,9>. The cDNA of this clone contains an open reading 
frame encoding amino acids 344-389 of topoi (see Results) and was cloned into 
the pEV-vrfl expression vector*26'. Plasmids carrying the Α-sequence were 
introduced into E. coli RRl(pRK248cIts) expressing a temperature-sensitive Xcl 
repressor. Upon heat induction from 30°C to 42°C for 3 h, large amounts of a 33-
kD polypeptide (the A-fragmcnt) were synthesized. In addition to the 246 amino 
acids homologous to topoi, the polypeptide contains four amino-terminal and 21 
carboxyl-terminal amino acids not related to the topoi sequence. 
Gel electrophoresis, protein blotting and detection of antigens 
SDS-PAGE and transfer of proteins from 13% Polyacrylamide gels onto nitro­
cellulose sheets was performed as described by Habets et al.<2C). For the detection 
of antigen, the protein blots were treated and processed as described'27'. 
DNA sequence analysis 
cDNA fragments were digested with a variety of restriction enzymes. DNA 
fragments were ligated into the polylinker region of M13 mpl8<28). Sequence 
analysis of the DNA fragments was performed by the dideoxy chain termination 
method'2". 
Results 
Isolation and expression of cDNA clones 
Serum from a patient with systemic sclerosis was used to screen a Xgtll cDNA 
expression library of human placenta for clones encoding topoi using standard 
methods previously described by Habets et al.'23'. One putative topoi clone with an 
insert of 1.2 kbp, referred to as λΗΤοροΒ, was identified. 
A number of longer cDNAs were obtained by rescreening the cDNA library with 
λΗΤοροΒ as hybridization probe. One of these clones, referred to as λΗΤοροΑ, 
contained an insert of 3.0 kbp. The isolated insert of λΗΤοροΑ was recloned into 
the осшНІ-sile of the pET-3c plasmid vector (see Materials and Methods) to yield 
pEHTopoA. 
Lysogens containing phage λΗΤοροΒ produced a ß-galactosidase fusion protein 
(HTopoB protein) with an apparent mol.wt of about 123 kD. 
Induced BL21(DE3) harboring pEHTopoA produced a polypeptide (HTopoA 
protein) with an apparent mol.wt of 74kD (fig. 1). Next to a large amount of this 
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protein the induced pEHTopoA lysates contained three additional protein products 
of 56, 42, and 34 kD, respectively, that could not be detected in lysates of the 
induced wild type. We assume that these proteins are proteolytic degradation 
fragments of the 74-kD HTopoA protein. 
kD 
94 
67 
43 
30 
20-1 
14-4 ^ £ 
Fig. 1. Expression of pEHTopoA in BL2I(DE3). Coomassie brilliant 
blueslained 13% SDS/polyacrylamide gel of a crude BL21(DE3) lysale 
containing pET-3c as a control (lane I ) or pEHTopoA (lane 2). In both 
cases the bacteria were harvested after induction for 3 hours at 37 С 
with 0-4 ілм IPTG. M, mol. wl markers (in kD). 
Identification of the cDNA clones 
DNA sequencing of λΗΤοροΑ and λΗΤοροΒ established that we had isolated 
clones encoding part of topoi. The DNA sequences of HTopoA and HTopoB were 
completely identical with the corresponding parts in the full-length clone TIB 
published by D'Arpa et al.tl9). The relative position of the HTopol sequences to 
TIB are shown in fig. 2. The clone HTopoB codes for 109 amino acids located at 
the carboxyterminal end of topoi. HTopoA contains in its 5'-scclion an open 
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reading frame of 2091 bp flanked by 900 non-coding nucleotides at the З'-end. 
The HTopoA protein contains amino acids 70-765 of the topoi protein fused to 
only 18 amino acids encoded by the vector and linker sequences (fig. 3). The 
calculated mol.wt of this protein is 84.2 kD, comprised of a 1.9 kD peptide 
encoded by the vector linked to 82.3 kD of the topoi protein. 
5' 3' 
О 212 2509 3645 
I ^ 1 TIB 
41 θ 340Э 
2ΙΘΟ 3333 
HTopoA 
HTopoB 
124 1 2041 3426 
О 1000 2000 3000 3645 bp 
Fig. 2. Schematic representation of the cDNA clones HTopoA and HTopoB and comparison with the 
full-length cDNA clone TIB published by D'Arpa el al. (1988). The relative position of the cDNA A-
sequence is indicated as well. Regions coding for topoi sequences are indicated by solid bars. The 
open box in the Α-sequence represents the out of frame part of the coding sequence of topoi. The 
premature slop in the open reading frame in the Α-sequence is indicated by an asterisk. The 5' and 3' 
noncoding regions are indicated by thin lines. 
5' fl/del Nhel pET-3c BamHl EcoHl Topoi 3' 
r.CG G.Í ...CAT.ATG.GCT.AGC.ATG.ACT.GGT.GGA.CAG.CAA.ATG.GGT.C G.АТС.CGA.ATT.CGG.GCG.GG 
LJL 
С. AAA. GAT. GGA. 
A . S . M . T . G . G . Q . Q . M . G . R . I . R . I . R . A . C 
(Ь) Ι ΙΘ 
70 765 
Fig. 3. (a) Nucleotide and amino acid sequences at the protein start point of cloned HTopoA in the 
pET-3c translation vector (pEHTopoA). The boxed nucleotide sequences at the 5'- and 3'- sites 
indicate the sequences belonging to the pET-3c vector and the topol cDNA clone region, respectively. 
The first 11 amino acids of the fusion protein are derived from the gene 10 protein. The intervening 
sequence originated from linkers. Locations of the Nde\, Nhel, BamHl and EcoRl sites are shown, (b) 
Schematic representation of the HTopoA protein. The fusion part consist of 18 amino acids followed 
by amino acids 70-765 of the native topol protein. 
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Reactivity of autoimmune sera with the HTopoA protein 
Using the immunoblotting technique with a HeLa S3 total nuclear protein extract 
as antigen source'20', sera from patients with several connective tissue diseases 
were screened for the presence of anti-topol antibodies'30'. Fig. 4a shows an 
example of such an analysis. In this way we selected 85 anti-topol sera which 
were subsequently probed on immunoblots containing the HTopoA protein. A 
typical example of the staining pattern of these sera on such immunoblots is 
shown in fig. 4b, lane 2. A positive immunoreaction with the 74-kD protein was 
obtained with 82 of the 85 sera (=96%). All these sera not only recognized the 74 
kD protein but also the putative degradation products of 56, 42, and 34kD (see 
fig. 1, lane 2). 
( a ) ( b ) 
1 2 3 4 1 2 3 4 
Topoi в 
CENP-B Ш 74 
70 kD 
56 
42 
34 
A 
A' 
B" 
CENP-A 
to» 
Fig. 4. (a) Characterization of human autoimmune sera Western blots containing HeLa total nuclear 
proteins were probed with a normal human serum (lane 1), systemic sclerosis serum Z28 showing the 
topoi band at around 100 kD Gane 2). anti-Ul, U2 RNP serum V26 showing the RNP proteins 70K, 
A. A' and B" (lane 3), or CREST serum B39 decorating the CENP-A band (19 kD) and the CENP-B 
ban (80 kD) Gane 4). 
(Ь) Analysis of human autoimmune sera on immunoblots containing total proteins of induced BL21 
(DE3)/pEHTopoA Lane 1, normal human serum, lane 2, systemic sclerosis serum Z28, lane 3, anti-
Ul, U2 RNP serum V26, lane 4, CREST serum B39. The antibody-antigen complexes were detected 
with horseradish peroxidase-conjugaled second antibodies 
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By comparison, only 85% of the sera that were positive on the immunoblot 
reacted positively in the Scl-70 immunodiffusion test<31). Also the three sera that 
were anti-topol-positive on a HeLa immunoblot but did not react with the 
recombinant antigen were negative in this immunodiffusion test. 
Reactivity of systemic sclerosis sera with the HTopoA protein 
From 40 patients in the group of 85 studied we could obtain a definite diagnosis 
systemic sclerosis according to the ARA criteria"2'. All these sera showed a strong 
immunoreactivity with the HTopoA protein. An analogous control experiment was 
performed with 23 sera from patients with a definite diagnosis of systemic 
sclerosis that were negative for anti-topol antibodies on a HeLa immunoblot. 
None of these 23 sera did react with HTopoA protein or its degradation products. 
These results indicate that both types of immunoblots display a comparable 
sensitivity for detecting anti-topol autoantibodies in patient sera. 
Autoimmune epitope distribution 
To obtain more information about the autoimmune epitope distribution on topoi, 
immunoblots containing either the HTopoA protein, the HTopoB protein or the A-
fragmenl were probed with anti-topol positive sera. All proteins were expressed as 
described in Materials and Methods. As shown in Table 1 three reaction patterns 
were found, indicating that the various sera recognized different epitopes. 
Tabi« 1: Immunoreactivity of antMopol-positivt sera with the HTopoA protein, the HTopoB protein of the A 
fragment 
Immunoreactivity of anti-topol sera with: 
HTopoA protein HTopoB protein A-fragment л (sera) 
+ + + 38 
+ + 7 
+ - - 8 
+ + - 0 
Serum F14 is placed in the group of sera that gave a positive immunoreaction with all three proteins. 
Seventy-two percent of the sera were found to be immunoreactive with all three 
proteins, 15% reacted with both the HTopoA protein and the A-fragment but 
contained no detectable level of antibody directed against the protein encoded by 
HTopoB, whereas another 13% of the sera reacted only with the HTopoA protein. 
This finding indicates that topoi contains at least three different autoimmune 
epitope regions, which are distributed over the entire protein (fig. 5). 
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7 0 3 4 4 5Θ9 657 765 
Fig. 5. Map of the different epitope regions (ER) on the HTopoA protein as recognized by sera from 
patients with anti-topol autoantibodies. The numbering of amino acids (70-765) is derived from the 
full-length clone TIB (D'Arpa et al., 1988). Q ER-1; Щ ER-3; ГД ER-2. 
One epitope region (ER) has to be situated on the A-fragment (ER-2), formed by 
amino acids 344-589, whereas a second region has to be located on the HTopoB 
protein which contains amino acids 657-765 (ER-3). As the HTopoA protein bears 
also one or more epitopes which are not present on the HTopoB protein or the A-
fragmenl, amino acids 70-344 and/or amino acids 589-657 are necessary to form a 
third ER (ER-1). In none of the sera used in this study could antibodies be 
detected merely directed against ER-3 without the simultaneous presence of 
autoantibodies directed against ER-1 and/or ER-2. 
We also performed a preliminary study on the epitope distribution of anti-topol 
positive sera from systemic sclerosis patients which had been followed longitudi­
nally for about 4 to 8 years. In most of these sera the antibody pattern appeared 
not to have changed in that period. In some patients, however, the titre of 
antibody against the various epitopes was found to have been changed significant­
ly during the course of the disease. This was observed, for example, in the serum 
samples of patient F14 (fig.6) who came to the hospital in 1984 as a severe case 
of Raynaud's disease. The serum of 1984 of this patient showed a very weak 
immunoreaction with both the HTopoA protein and the A-fragment. From 1985 
up to 1988 this reaction became stronger and clearly positive. In contrast, a 
significant level of antibody directed against the HTopoB protein (ER-3) was not 
seen until 1987. A three-fold increase of the HTopoB protein concentration on the 
immunoblots to enhance the sensitivity of the reaction gave identical results. 
FI4 
Γ 
I 2 3 4 5 I' 2 ' 3 ' 4 ' 5 
І ЫІ І І І I P 
Я Ж™ Н И И 
HTopoA protein 
A - f r a g m e n t 
Ш& HTopoB p r o t e i n 
Pig. 6. Characterization of several samples of the SSc serum of patient F14 on immunoblots containing 
the HTopoA protein (74 kD), the HTopoB protein (125 kD) or the A-fragmenl (33 kD). Samples were 
collected in 1984 Ganes Γ), 1985 flanes 2'). 1986 (lanes 3'). 1987 (lanes 4') and 1988 (lanes 5'). 
Control sera used were a normal human serum (lanes 1), anti-Sm serum C45 (lanes 2). CREST serum 
B39 (lanes 3) and SSc sera Z28 (lanes 4) and R25 (lanes 5). The antibody-antigen complexes were 
delected with horseradish peroxidase-conjugaled second antibodies. 
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Discussion 
Using autoantibodies from a patient with systemic sclerosis we isolated a human 
cDNA clone (HTopoB) encoding DNA topoi from a Xgtll expression library. 
Screening of the same library with this clone revealed additional recombinants 
with a longer cDNA insert, the longest being HTopoA. The cDNA HTopoA 
covered 2091 nucleotides (695 amino acids) of the coding sequence of topoi 
which consists of 2297 nucleotides (765 amino acids)0". This cDNA was 
expressed in the pET-3c expression vector giving rise to a protein (HTopoA 
protein) of 84.2 kD. On SDS-PAGE the HTopoA protein migrated as a 
polypeptide of approximately 74 kD. A similar aberrant behavior of a topoi 
recombinant protein on an SDS Polyacrylamide gel has been described by D'Arpa 
et al.ll,). Next to the 74-kD protein, lysates of bacteria expressing HTopoA 
contained several smaller prominent polypeptides (fig. 1). Their presence can be 
explained either by assuming partial proteolytic cleavage of the 74-kD protein or 
by the use of alternative ATG initiation codons. 
The HTopoA protein was recognized by 96% of our anti-topol-positive sera. 
Three sera, scored as weakly positive with topoi on a HeLa immunoblot, did not 
react with the HTopoA protein. This discrepancy can be explained in several 
ways. One explanation is that these sera had been scored as false-positive for 
topoi because of an immunorcaction with another protein migrating in the same 
mol. wt region as HeLa topoi. As these sera were also negative in the Scl-70 
immunodiffusion test, this possibility seems the most likely one. Another possible 
explanation is that the sera do react with topoi but with an epitope present on 
amino acids 1-70, i.e. that part of topoi that is missing in the HTopoA protein. 
Nevertheless, the finding that the HTopoA protein is recognized by at least 96% 
of our anti-topol sera makes this recombinant protein a good substitute for native 
eukaryotic topoi in the screening for anti-topol antibodies of sera from patients 
with connective tissue diseases. Since large amounts of purified HTopoA protein 
can be obtained in a relative simple and easy way this antigen might be very 
useful in future diagnostic tests. Furthermore, our results confirm an earlier report 
that about 30% of systemic sclerosis patients do not seem to contain detectable 
levels of anti-topol antibodies'14). Even the use of a very sensitive ELISA test with 
the recombinant topoi as antigen failed to show the presence of anti-topol 
antibodies in these systemic sclerosis patients (data not shown). 
In analyzing the immunoreaction patterns of anti-topol sera with either the 
HTopoA protein, the HTopoB protein or the A-fragment we found that 72% of 
the sera contained antibodies directed against all epitope regions on the HTopoA 
protein. The fact that in the other sera antibodies could be detected against ER-1 
and/or ER-2 without the presence of antibodies against ER-3 suggests that the 
antibody reaction against the various ERs is not developed simultaneously. 
A follow-up study of sera obtained between 1984 and 1988 from a systemic 
sclerosis patient (F14) demonstrated that in the serum sample taken in 1984 no 
antibodies could be detected against ER-3. Only 3 years after the first detection of 
autoantibodies against ER-1 and ER-2, could autoantibodies against ER-3 be 
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detected. As the HTopoB protein is a ß-galactosidase fusion protein we con-
sidered the possibility that these results were due to a development of antibodies 
against ß-galactosidase. However, all serum samples were negative for the 
presence of such antibodies (data not shown). One of the possible explanations for 
our finding is that the autoimmune epitope on ER-3 was developed in a later 
phase of the disease as compared with the other autoimmune epitopes on topoi. 
However, this conclusion should be interpreted with great care, as in these 
experiments one is comparing the immunoreactivity of different types of anti-
bodies on different antigens. 
Recently, Eng, Pandit & Stemglanz(33) and Lynn et al.(34) have mapped the tyrosine 
residue in yeast topoi that is responsible for the formation of the covalent 
cnzymc-DNA intermediate. On basis of alignment of topoi sequences of human 
and yeast, these investigators proposed Tyr-723 in human topoi to be the equival-
ent active site tyrosine. This means that only autoantibodies against the HTopoB 
protein (ER-3) may interact with or near the active center and possibly inhibit 
topoi activity. Further studies are now in progress to map the epitope regions in 
more detail in order to select those autoimmune sera that recognize the active site 
of topoi. Such knowledge may contribute to a better insight into the progression 
of systemic sclerosis. 
Note 
Shortly after this paper was accepted for publication, another description В cell 
epitope on DNA topoisomerase I appeared (Maul GG, Jimenez SA, Riggs E, 
Ziemnicka-Kotula D. Proc. Natl. Acad. Sci. USA, 1989;86:8492). This auto-
cpilope is contained in the region defined by us as ER-3 (see fig. 5). 
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Antitopoisomerase I antibody titers and treatment 
A. Rebound of antitopoisomerase I antibodies titers after plasma 
exchange therapy in a patient with systemic sclerosis. 
Serum levels of a specific antibody induce a negative feedback on the synthesis of 
antibody of the same specificity0,2'. If this feedback inhibition of antibody 
synthesis is reduced by diminishing the concentration of antibody in the circula­
tion by plasma exchange (PE) an enhancement of antibody synthesis, also termed 
"antibody rebound" occurs. This rebound phenomenon has been shown to occur 
amongst others in autoimmune mediated diseases such as SLE(3). 
Plasma exchange, single or combined with immunosuppressive therapy, has been 
used in the treatment of systemic sclerosis (SSc)(4"6), although its effectiveness in 
this disorder remains questionable'71. Changes in autoantibody concentrations 
during PE-therapy of scleroderma patients have been used to monitor the efficacy 
of P E ( 0 ) . 
We would like to present the case of a 50 year old woman who had Raynaud's 
phenomenon since the age of 30 and a 4-year history of sclerodactyly. In a few 
months time skin thickening progressed to upper arms, face, neck and chest. A 
diagnosis of rapidly progressing SSc was made. Treatment with azathioprine, 100 
mg (2 mg/kg) daily, was initialed. Four weeks thereafter, as no improvement 
occurred, PE therapy was started. At that time laboratory results included hemo­
globin 6.4 mmol/L, white blood cell count 7,300/mm3, platelets 428 χ ÌO'/L, 
Westergren 48 mm/hr. and creatinine clearance 70 ml/min. Total hemolytic 
complement, circulating immune complex levels, C3/C4 complement components 
and concentrations of immunoglobulins (Ig) A, M and G were within normal 
range. Both IgG and IgA isotypes of antitopoisomerase I antibodies (ATA) could 
be detected, the IgM isotype was below detection level. Radiologic examination 
disclosed reduced peristalsis of the oesophagus; chest X-ray and pulmonary 
function tests were within normal limits. During a 29 day period 11 PE sessions 
were performed. At each session 2000 ml of plasma was exchanged using 
cryoglobulin free plasma for replacement. The interval between PE sessions varied 
from 1 to 5 days. Before the start of azathioprine treatment and immediately 
before and after each PE, total IgA and IgG concentrations were established, as 
well as IgG and IgA ATA titers, using an enzyme-linked immunosorbent assay 
(ELISA) with a recombinant topoisomerase I as antigen source(e>. After the 11th 
session PE was stopped on patient's request. Azathioprine medication was given 
during the whole period of PE-lrcatment and continued after the cessation of this 
treatment. 
No change in titers of total IgA and IgG or ATA could be detected before and 
after 4 weeks of azathioprine treatment, when PE-therapy was started. After each 
PE however, a reduction of IgG and IgA ATA titers was found (figures la and 
lb). IgG ATA titers decreased on average 40% ± 16% (range 18% - 72%) and 
IgA ATA titers 51% ± 14% (range 29% - 77%). Total IgA and IgG levels 
decreased in the same amount as IgA and IgG ATA concentrations. Within 1 to 5 
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days after each PE, ATA titers increased to 80% - 125% of pre-PE levels; 
although an increase in total IgA and IgG was also observed, (his increase never 
exceeded pre-PE values. Five days after the last PE, IgG and IgA ATA levels 
were respectively 77% and 83% of the initial values. Five weeks after the last PE, 
(he patient still being on azathioprine, both IgG and IgA ATA levels equalled 
pretreatment values. No changes in the physical condition of the patient could be 
observed during the PE-treatment. 
To our knowledge this rebound of ATA after PE in a patient with systemic 
sclerosis has not been reported before. The mechanisms of antibody rebound, 
sometimes leading to post-PE concentrations exceeding pre-treatment values, 
remain unsolved. A conjectural explanation might be clonal expansion of antibody 
producing B-cells, caused by re-exposure of antigenic determinants after a 
decrease in antibody levels or by removing blocking anti-idiotypic antibody™. 
Therefore, PE applied in the treatment of autoimmune diseases is usually com-
bined with cytotoxic drugs to inhibit B-cell proliferation. In our patient azathio-
prine 100 mg daily could not accomplish a decline of ATA titers and could not 
prevent the rapid increase of ATA after PE as well. However, 5 days after the last 
PE, the combination of azathioprine and PE had caused a reduction of about 20% 
of both IgG and IgA ATA titers. In the study performed by Ferri et al.(5), who 
treated 6 scleroderma patients with PE without concomitant cytotoxic treatment, 
autoantibody levels were largely unaffected after a prolonged period of PE-
treatment despite a clinical benefit observed in their patients. It was suggested that 
the unchanged antibody concentration could be attributed to a rapid resynthesis of 
autoantibodies rather than to insufficient PE. The rebound of ATA titers observed 
in our patient confirms this presumption. Therefore, in monitoring autoantibody 
levels during PE-treatment in SSc, rebound of ATA and presumably all other 
auto-antibodies, should be considered. 
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Figure 1a IgG anti-topoisomerase antibody titers 
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Antitoposisomerase antibody titers were determined by enzyme linked 
immunosorbent assay (ELISA) in the serum before and immediately after 
plasma exchange (PE) treatment. The results are given in optical density 
units (OD), read at 450 nm. The value of pooled normal human serum in this 
experiment was about 0.1. After day 29 plasma exchange treatment was 
discontinued. 
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В. Effects of low dose methotrexate treatment on antitopoisomerase I 
antibody titers in systemic sclerosis 
Summary 
Aims - To study the effects of methotrexate (MTX) treatment on antitopoisome­
rase I antibody (ATA) titers and to investigate the relation between ATA titers and 
response to treatment in scleroderma patients. 
Patients and methods - Out of 29 scleroderma patients who participated in a 
double blind study comparing MTX with placebo, 16 patients were positive for 
antitopoisomerase I antibodies and were involved in this study. The patients 
received either 15 mg MTX or placebo weekly via intramuscular (im) injection. 
After 24 and 48 weeks of treatment response was evaluated according to predeter­
mined criteria, consisting of >30% improvement of skin score or general well-
being, or improvement of >15% of single breath diffusion capacity for carbon 
monoxide. Patients who were considered to respond after 24 weeks on initial 
treatment continued with the same treatment to the end of the trial at week 48; 
patients who did not respond on placebo after 24 weeks continued with 15 mg 
MTX weekly from then on; patients who did not respond on 15 mg MTX con­
tinued with an increased dose of 25 mg MTX until week 48. At study entry and 
after 24 and 48 weeks ATA titers were measured using an ELISA with a recom­
binant topoisomerase I as antigen source. 
Results - No significant differences were observed in pretreatment ATA titers 
between scleroderma patients receiving MTX or placebo. ATA titers decreased 
equally during MTX and placebo treatment. Likewise, a similar reduction of ATA 
titers was found in patients responding on MTX treatment and in patients not 
responding on MTX treatment. 
Conclusion -ATA titers are not useful for monitoring MTX treatment in SSc. 
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Introduction 
Systemic sclerosis (scleroderma, SSc) is a connective tissue disease characterized 
by fibrosis and vascular obliteration in the skin and internal organs. SSc is a rare 
disease with an estimated annual incidence rate of 20 new cases per million0'. 
The pathogenesis of the disease remains unknown but mechanisms of enhanced 
extracellular matrix accumulation, vascular endothelial injury and immune cell 
activation seem to be involved*21. Evidence for immune cell activation is obtained 
amongst others by the presence of antinuclear antibodies in over 90% of sera of 
patients with SSc(3). Antitopoisomerase I antibodies (ATA) are a specific serolo-
gical maker for SSc(4) and can be detected in 28 - 59% of scleroderma patients 
with the diffuse cutaneous form with skin thickening proximal of elbows and/or 
knees'5"7'. ATA also occur in approximately 14% in patients with limited disease, 
that is with skin involvement of the distal extremities only(8). Diffuse SSc is 
associated with more frequent occurrence of internal organ involvement and hence 
adversely affects disease outcome"""1. Therefore, the presence of anlitopo in 
scleroderma patients is thought to be indicative of a worse prognosis. 
Although a wide variety of drugs have been advocated in the treatment of SSc, no 
single drug has been shown to be effective in this disease. Recently, we reported 
on the results of a randomized double blind trial in which low dose methotrexate 
(MTX) was compared with placebo in the treatment of patients with SSc. It was 
shown that MTX was superior to placebo"2'. 
The aims of this study were to determine the effects of methotrexate (MTX) 
treatment on antitopoisomerase I antibody (ATA) tilers and to investigate the 
relation between ATA titers and response to treatment in scleroderma patients. 
Patients and methods 
The details of the clinical study have been described elsewhere02'. In short, 29 
patients meeting the preliminary criteria for the classification of SSc03' were 
enrolled in a 48-week, randomized, double-blind trial comparing methotrexate 
with placebo. Drugs with potential disease-modifying effects were discontinued at 
least three months prior to study entry. Dosages of allowed concurrent treatment 
(including prednisone <10 mg/day and non-steroidal anti-inflammatory drugs) was 
kept stable during the trial. Patients were randomly allocated to receive cither 15 
mg MTX (n=17) or placebo (n=12) administered weekly as intramuscular (im) 
injection. Clinical and laboratory data were gathered by one observer (FvdH) 
every 4 weeks. After 24 and 48 weeks, treatment was evaluated according to 
predetermined criteria. Good response was defined as >30% improvement 
occurring in either skin score (using the skin score method as developed by Steen 
et al.04' or patients' global assessment expressed in a visual analogue scale (0 mm 
= low general well-being and 100 mm = optimal general well-being) or impro-
vement of >15% of diffusion capacity for carbon monoxide (DLC0), whenever not 
accompanied by persistence of digital ulcerations or worsening of DLco by >15%. 
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Patients who were considered to respond on initial treatment continued with the 
same treatment to the end of the trial at week 48; patients who did not respond on 
placebo continued with 15 mg MTX im weekly from then on, patients who did 
not respond on 15 mg MTX continued with an increased dose of 25 mg MTX 
until week 48, at which time a final evaluation took place. At study entry, in sera 
of 16 of the 29 patients antitopo could be detected on immunoblotting and 
quantified by ELISA(,5). 
Antitopoisomerase I antibody measurements 
Serum samples obtained at study entry and after 24 and 48 weeks of treatment 
were used for measuring antitopo-titers. Serum samples were stored at -70°C, and 
after the study was completed, all sera were thawed and processed at the same 
time. For detection of ATA activity an ELISA was established using a recom­
binant topo protein as antigen source"5*. Optimal concentrations of antigen, patient 
sera and conjugates were established after appropriate chess board titrations. The 
procedure was performed according to the method previously described06'. Plates 
were read on a Bio-Rad model 2550 ELISA reader at 450 nm. OD4 5 0 was 
arbitrarily defined as 1 unit. All sera were tested in triplicate in different dilutions 
and the results were averaged. Interassay and intra-assay variabilities never 
exceeded 15%. 
Statistical analysis 
Differences in demographic characteristics between the two treatment groups were 
judged using the X2 test for nominal variations. Differences in ΑΤΑ-titers between 
groups at baseline were calculated with the Mann-Whitney test. Comparison of 
changes in ΑΤΑ-titers between the groups at baseline and during follow-up were 
calculated with the two sample Τ test. Ρ values <0.05 were considered significant. 
Results 
As none of the 13 patients, in which at study entry ATA activity was not detect­
able either via immunoblotting had antitopotiters detectable on ELISA at any 
measuring point during trial, this study focusses only on the 16 antitopo positive 
patients. The demographic characteristics of the patients are shown in table 1. 
Nine patients received methotrexate and 7 received placebo treatment initially. No 
significant changes were observed in demographic characteristics between the two 
treatment groups. The disease course of the patients is depicted in figure 1. 
Seven out of nine patients who started treatment with 15 mg MTX weekly at 
study entry completed the first 24 weeks of the trial. Two patient were withdrawn, 
one because of renal crisis and one because of severe headache. At week 24, three 
patients were considered to be responders and 4 nonresponders, according to the 
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above mentioned criteria. The four not responding patients were treated with 25 
mg MTX weekly from then on; one of these patients died because of respiratory 
insufficiency due to progressive fibrosis, the remaining three did not respond on 
the enhanced dose of MTX at week 48. 
Table 1: Demographic characteristics of patients positive for antltopolsomerase I 
antibodies at study entry 
Methotrexate Placebo 
number 9 7 
mean age (SD), years 53 8 (8 2) 56.3 (9 2) 
male/female 5/4 2/5 
limited/diffuse* 6/3 5/2 
dis duration <1 year/>l year** 4/5 2/5 
limited: skin thickening distal to elbows and/or knees or face only, 
diffuse: skin thickening proximal to elbows and/or knees 
dis. duration, disease duration as assessed from first signs of skin thickening 
Six out of the seven patients initially treated with placebo, completed the first 24 
weeks of the trial; one patient was withdrawn due to renal crisis. After 24 weeks, 
one of these patients was considered to respond; the five remaining patients were 
treated with 15 mg MTX from then on and two of these were considered 
responder as yet on week 48. ATA titers at weeks 24 and 48 of the latter patients 
were included in the analysis of responders and nonresponders on 15 mg MTX 
treatment. At the end of the trial, six patients could be classified as responders (5 
on MTX treatment, 1 on placebo treatment). 
Twelve patients received 15 mg MTX for at least 24 weeks; this group included 
seven patients who where treated with MTX from week 0 to 24 and five patients 
treated with MTX from week 24 to 48. 
ATA titers from patients that received placebo or MTX, and from patients that 
responded or did not respond during the trial are presented in table 2. No signifi­
cant difference was observed in pretreatment ATA titers between the placebo and 
MTX treated group; likewise, no significant differences were found between 
responders and nonresponders. Compared with baseline values, after 24 weeks of 
treatment ΑΤΑ-titers decreased in the placebo and in the MTX group. The 
difference of changes between the two groups was 9.7 ± 17.4 (mean ± standard 
error of the mean, p=0.59). ΑΤΑ-titers also decreased in patients that responded 
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Table 2: Antitopoisomerase I antibody (ATA) titers and percent change after 24 
weeks In patients receiving either methotrexate or placebo treatment, and In 
responders and nonresponders. 
ATA titers (U) % changes at 
24 weeks 
mean difference of 
changes between groups 
Placebo (n=6) 
Methotrexate (n=12) 
1520 (220-17493)* -14 (-43,38) 
3392 (954^*138) -28 (-60,74) 9 7 ± 17 4 (p=0 59) 
Responders (n=6) 
Nonresponders (n=6) 
1179 (220-3872)** -40 (-60,8) 
1357 (552-17494) -24 (-38,74) 26 0 ± 19 7 (p=0 22) 
Values of ATA titers and % changes are given as median with between parentheses minimum and 
maximum values Differences of changes are given as mean ± standard error of the mean ATA titers 
are presented as units, OD430 was arbitrarily defined as 1 unit 
* p=0 18 between placebo and MTX treated group, ** p=0 82 between responders and non responders. 
Table 3: Antitopoisomerase I antibody (ATA) titers at study entry In patients with 
disease duration <1 year and >1 year, and In patients with limited and 
diffuse disease. 
ATA titers (U) P-value 
between groups 
Disease duration <1 year (n=6) 
Disease duration ¿1 year (n=10) 
3440 (768-17493) 
1309 (220-3872) 
009 
Limited disease (n=ll) 
Diffuse disease (n=5) 
1098 (220-17493) 
3296 (1520-3584) 
031 
Values of ATA titers are given as median with between parentheses minimum and maximum values 
* limited disease skin thickening distal to elbows and/or knees or face only 
diffuse disease skin thickening proximal to elbows and/or knees 
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to either 15 mg MTX (n=5) or placebo (n=l) and in the patients that not 
responded to 15 mg MTX treatment. The mean difference of changes between the 
two groups was 26.0 ± 19.7 (p=0.22). No difference in results was obtained when 
ATA-titers of the only patient responding on placebo were omitted in the calcula­
tions (data not shown). 
We also compared ΑΤΑ-titers at study entry of patients with disease duration <1 
year and >1 year, and of patients with limited and diffuse disease (Table 3). There 
was a tendency of higher median ΑΤΑ-titers in the patients with disease duration 
<1 year as compared to patients with longer disease duration (p=0.09); patients 
with diffuse disease had no significant different ΑΤΑ-titers as compared with 
patients with limited disease (p=0.31). 
Discussion 
Serial assessments of antibody levels in autoimmune rheumatic diseases such as 
anti-dsDNA in systemic lupus erythematosus07"1" and anticytoplasmic antibodies 
in Wegener's disease120' can be helpful in monitoring disease activity. An increase 
of the titer of one of these autoantibodies may precede a disease exacerbation; 
response to treatment may be accompanied by a decline of autoantibody titer. 
Both autoantibodies have a high disease specificity, which is also the case for the 
ATA in scleroderma'4'. Antitopoisomerase I antibodies are reported to occur 
predominantly in patients with diffuse scleroderma. However, in this study only 5 
of the 16 patients with ATA could be classified as diffuse SSc. ATA are as­
sociated with a bad disease outcome"'"·20. As far as we know this is the first 
study that examined the relation between the ATA titers and efficacy of treatment 
in patients with systemic sclerosis. 
We found a reduction of ΑΤΑ-titers both in patients receiving MTX and patients 
receiving placebo for 24 weeks. The difference of the changes between the two 
groups after 24 weeks was not significant indicating that low-dose MTX cannot 
be the cause for the decline in ATA-titers. 
There was no significant difference in ΑΤΑ-titers between responders and 
nonresponders at the start of either MTX or placebo treatment; therefore response 
to treatment is not predicted by pretreatment ATA-titers. 
After 24 weeks of treatment, ATA-titers decreased equally in the responders and 
nonresponders. This indicates that ATA-titers do not reflect clinical response as 
defined by criteria consisting of >30% improvement of skin score or general well-
being, or >15% improvement of DL
co
, that we applied in this study. 
Only in three patients an increase of ATA-titers was observed. This increase could 
not be related to MTX or placebo treatment, diffuse or limited disease, or disease 
duration <1 year or >1 year. ATA-titers decreased in all the other patients studied 
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during follow-up, irrespective of MTX or placebo treatment, and irrespective of 
response to treatment. We have no good explanation for this decrease but it could 
be explained by an inverse relation between ΑΤΑ-titers and disease duration. 
Some support for this explanation is derived from the fact that there was a 
tendency of higher ΑΤΑ-titers at study entry in patients with disease duration <1 
year as compared to patients with longer disease duration. However, ATA-titer 
measurements in larger groups are required to substantiate this assumption. 
On the basis of the results of this study, we conclude that ATA titers are not 
useful in monitoring MTX treatment in SSc. 
100 
Antitopoisomerase I antibody titers and treatment 
REFERENCES 
1. Steen VD, Conte С, Santoro D, et al : Twenty-year incidence survey of systemic sclerosis, 
(abstract) Arthritis Rheum 1988,31 S57. 
2. LeRoy EC: Pathogenesis of systemic sclerosis In· McCarty DJ, Koopman WJ, eds. Arthritis 
and Allied Conditions Twelfth ed Philadelphia Lea & Febiger, 1993,1293-1297 
3. Tan EM, Rodnan GP, Gana I, et al Diversity of antinuclear antibodies in progressive 
systemic sclerosis Arthritis Rheum 1980,23 617-625 
4. Jarzabek-Chorelska, Blaszczyk M, Jablonska S, et al · Sci 70 antibody - a specific marker of 
systemic sclerosis. Br J Dermatol 1986,115 393-401. 
5. Van Venrooij WJ, Stapel OS, Houben H, et al : Scl-86, a marker for diffuse scleroderma. J 
Clin Invest 1985,75 1053-1060. 
6. Steen VD, Powell DL, Medsger TA Jr: Clinical correlations and prognoses based on serum 
autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988;31:196-203. 
7. Weiner ES, Eamshaw WC, Seneca! JL, el al.: Clinical associations of anlicentromere 
antibodies and antibodies to topoi some rase I. A study of 355 patients Arthritis Rheum 
1988,31.378-385 
8. Medsger ТА, Jr. Systemic sclerosis (scleroderma), localized forms of scleroderma, and cal­
cinosis In: McCarty DJ, Koopman WJ, eds Arthritis and Allied Conditions Twelfth ed. 
Philadelphia: Lea & Febiger, 1993,1253-1292 
9. Bamett AJ, Miller MH, Littlejohn GO· A survival study of patients with scleroderma 
diagnosed over 30 years (1953-1983) the value of a simple cutaneous classification in the 
early stages of the disease J Rheumatol 1988,15 276-283 
10. Medsger ТА Jr, Mase AT, Rodnan GP, et al Survival with systemic sclerosis (scleroderma) 
A life-table analysis of clinical and demographic factors in 309 patients Ann Intern Med 
1971,75 369-376 
11. Giordano M, Valentini G, Migliatesi S, et al Different antibody patterns and different 
prognoses in patients with scleroderma with different extent of skin sclerosis J Rheumatol 
1986,13 911-916 
12. Van den Hoogen FHJ, Boerbooms AMT, Swaak AJG, et al.: Methotrexate versus placebo in 
the treatment of systemic sclerosis. A forty-eight-week randomized double blind trial. 
Submitted 
13. Masi AT, Rodnan GP, Medsger TA Jr, et al : Preliminary entena for the classification of 
systemic sclerosis (scleroderma). Arthritis Rheum 1980,23 581-590. 
14. Steen VD, Medsger ThA, Rodnan GP: D-penicillamine therapy in progressive systemic 
sclerosis (scleroderma). Ann Intern Med 1982,97 652-659. 
15 Verheijen R, Van den Hoogen FHJ, Beijer R, el al. A recombinant topoisomerase I used for 
autoantibody detection in sera from patients with systemic sclerosis. Clin Exp Immunol 
1990,80 38^3. 
16. Verheijen R, de Jong BAW, Oberyé EHH, et al Molecular cloning of a major CENP-B 
epitope and its use for the detection of anlicentromere autoantibodies. Mol Biol Rep 1992;-
16-49-59. 
17 Swaak AJG, Aarden LA, Stati us van Eps LW, et al. Anti-dsDNA and complement profiles as 
prognostic guides in systemic lupus erythematosus Arthritis Rheum 1979;22 226-235 
18. Swaak AJG, Groenwold J, Bronsveld W: Predictive value of complement profiles and anti-
dsDNA in systemic lupus erythematosus. Ann Rheum Dis 1986;45 359-366. 
19. Ter Borg EJ, Horst G, Hummel EJ, et al : Measurement of increases in anti-double-stranded 
DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus 
Arthntis Rheum 199σ,33 634-643 
20. Nolle B, Specks U, Ludermann J, et al Anticytoplasmic autoantibodies: their immunodiagnos-
tic value in Wegener's granulomatosis Ann Intern Med 1989,111 28-40. 
21. Briggs DC, Vaughan RW, Welsh KI, et al. Immunogenelic prediction of pulmonary fibrosis m 
systemic sclerosis. Lancet 1991,338 661-662. 
101 

Chapter Vili 
Long-term follow-up of 46 patients with MCTD 
Evolution towards systemic sclerosis, systemic lupus erythematosus 
and rheumatoid arthritis 
Van den Hoogen FHJ, Spronk PE, Boerbooms AMTh, Boolsma H, De Rooij 
DJRAM, Kallenberg CM, Van de Putte LBA. Long-term follow-up of 46 patients 
with anti-(Ul)snRNP antibodies. Br J Rheumatol, in press. 

Long-term follow-up of MCTD patients 
Summary 
The records of 46 patients with anti-(Ul)snRNP antibodies and a minimal period 
of follow-up after first clinical presentation of at least five years were examined 
with emphasis on symptoms contributing to established criteria of systemic lupus 
erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA) or 
dermato- or polymyositis (DM/PM). At first clinical presentation 13 (28%) of the 
46 patients studied fulfilled ARA-criteria for SLE (n=10), RA (n=2) and SSc 
(n=l), and 33 (72%) were classified as mixed connective tissue disease (MCTD). 
During follow-up 18 patients initially classified as MCTD were now classified as 
SLE (n=5), SSc (n=7), RA (n=3), or a combination of these disorders (n=3). A 
transformation of MCTD towards these connective tissue diseases occurred 2.6 ± 
3 years (mean ± SD) after first clinical presentation. At the end of the follow-up 
period 67% of the patients fulfilled ARA criteria for SLE, SSc, RA or a combina-
tion of these diseases. 
The majority of patients with anti-(Ul)snRNP antibodies have or will develop a 
classified connective tissue disease within 5 years after clinical presentation. This 
undermines the concept of MCTD being a distinct clinical entity. 
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In 1972 Shaip et al. described a syndrome, which they called mixed connective 
tissue disease (MCTD), that was clinically denoted by features of two or more 
defined autoimmune connective tissue diseases, namely systemic lupus 
erythematosus (SLE), systemic sclerosis (scleroderma, SSc) and dermato- or 
polymyositis (DM/PM), and the presence of a high titer of circulating antibodies 
to an RNA-se sensitive extraclable nuclear antigen01. This antigen proved to be a 
ribonucleoprotein (RNP) that plays an important role on pre-messenger ribonu-
cleic acid (RNA)-splicing<2) and is composed of a small nuclear (sn) RNA desig-
nated Ul, and three or more distinct Ul-RNA binding proteins'3'. Immunoblot 
studies have shown that the immunorcactive sites are located on the protein 
moiety. Antibodies directed against the (Ul)snRNP (anti-(Ul)snRNP antibodies) 
are considered to be the hallmark of MCTD. Additional clinical features of 
MCTD appeared to be infrequent renal disease, good response to low doses of 
corticosteroids and a favorable prognosis10. However, since then the concept of 
MCTD being a truly distinct disease entity has been questioned in many reports. 
Some hold that MCTD should be viewed as a part of the spectrum of SLE rather 
than a different disease subset<4), while others have not found a close association 
between the mixed clinical characteristics of the different autoimmune connective 
tissue diseases and antibodies to RNP*5"7'. Anti-RNP antibodies arc not restricted 
to MCTD, but occur in other connective tissue diseases as well'4,8'"'. Occasionally 
anti-(Ul)snRNP antibodies have been reported in other autoimmune diseases'12'. 
Furthermore, many of the cases initially diagnosed as MCTD have evolved to SSc 
or SLE(6-713·14', and some have developed well defined overlap syndromes"5,16'. 
Since the concept of MCTD being a distinct clinical entity is still controversial 
and the diagnostic and prognostic value of anti-(Ul)snRNP antibodies are 
unresolved, the aim of this study was to evaluate the disease course of patients 
with anti-(Ul)snRNP antibodies during a minimal follow-up period of at least five 
years. 
Patients and methods 
Patients 
Patients with signs and symptoms indicating inflammatory connective tissue 
disease treated at or referred to the Departments of Rheumatology of the Univer-
sity Hospital or St. Maartenskliniek Nijmegen, or the Department of Clinical 
Immunology of the University Hospital Groningen between 1975 and 1986 were 
analyzed for the presence of antinuclear antibodies (ANA). AH sera with ANA 
activity were routinely analyzed for anlibodyspecificity by counterimmunoelectro-
pheresis (CIE) and from 1981 onwards also by immunoblotling. Patients positive 
for anti-(Ul)snRNP were selected for further analysis. 
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Methods 
Charts of all patients were examined according to a predetermined protocol with 
particular attention paid to the presenting symptoms and symptoms contributing to 
the well-defined classification criteria of SLE, RA, SSc and DM/PM 0 7 2", as well 
as to the presence of clinical and serologic manifestations characteristic of 
connective tissue diseases. During follow-up patients were seen at regular 
intervals; serologic parameters, that from 1980 onwards were measured yearly, 
consisted of rheumatoid factor (RF), ANA, anti-dsDNA antibodies, and anti-
(Ul)snRNP antibodies as assessed by CIE and immunoblotting. For each patient, 
clinical and serologic data were stored on a cumulative way. 
The presence of ANA was determined by indirect immunofluorescence using 
human fetal fibroblasts'2" or Hep2 cells as a substrate. Serum was considered 
ANA positive when a serum dilution of >1:40 on human fibroblasts and >1:10 on 
Hep2 cells appeared positive. Anti-dsDNA antibodies were considered positive 
when a positive immunofluorescence was obtained with a serum dilution of >1:10 
in the Crilhidia luciliae assay(22). Antibodies to extractable nuclear antigens (anti-
ENA) were detected by CIE according to Kurata and Tan<23) using a crude extract 
from rabbit thymus acetone powder as substrate and reference sera showing 
identity with the corresponding Center for Disease Control (CDC, Atlanta, GA) 
references. Immunoblotting was performed with extracts from HcLa cell nuclei as 
previously described'34'. Anti-(U1)RNP antibodies were considered when the 
70kDa and/or the A and/or the С band were present, anli-Sm antibodies in the 
presence of the D band with or without the BB' band, aniitopoisomcrase I 
antibodies in the presence of the 86kDa band and anticentromere antibodies in the 
presence of the 17kDa band. RF was considered positive when IgM-RF, measured 
by enzyme linked immunosorbent assay (ELISA), was >10 U/ml. 
Results 
Demographic characteristics 
In 49 patients anti-(Ul)snRNP antibodies could be detected on two consecutive 
occasions on both immunoblot and CIE. Three patients had moved and were lost 
for follow-up, leaving 46 patients with anti-(Ul)snRNP antibodies who at the lime 
of the study had a minimal follow-up period of five years. There were 33 females 
and 13 males. Mean age ± SD of the patients was 49 ± 15 years (range 2 4 - 8 1 
years) with a mean disease duration of 17 ± 6 years and an average period of 
follow-up of 15 ± 6 years. 
Diagnosis at clinical presentation 
At clinical presentation ten patients could be classified as having SLE, two 
patients as having RA and one as having SSc; the remaining 33 did not fulfil 
107 
Chapter Vili 
classification entena of any of these connective tissue diseases but could be 
designated MCTD according to Sharp's entena'". The presenting symptoms of the 
patients with a diagnosis of the vanous autoimmune diseases are depicted in 
Table 1. This shows that none of the presenting symptoms was specific for any of 
the autoimmune diseases studied. 
Table 1: Presenting symptoms In 46 patients with antl-(U1)snRNP-antlbodies, 
classified according to Initial diagnosis 
Raynaud's (N,%) 
Arthralgia (N,%) 
Artlinlis (N,%) 
Nephropathy (N,%) 
Discoid lesions (N,%) 
Puffy hands (N,%) 
MCTD 
(11=33) 
17 (52) 
14 (42) 
2(6) 
1 (3) 
1 (3) 
2(6) 
SLb 
(n=10) 
3 (30) 
5(50) 
2(20) 
0 
1 (10) 
1 (10) 
RA 
(n=2) 
1 (50) 
0 
2 (100) 
0 
0 
0 
SSc 
(n=l) 
1 (100) 
0 
0 
0 
0 
0 
MCTD mixed connective tissue disease, SLb systemic lupus erythematosus, 
RA rheumatoid arthritis, SSc systemic sclerosis 
Diagnosis at follow-up 
At the end of the follow-up penod, 18 (55%) of the 33 patients initially classified 
as MCTD could be diagnosed as having one or a combination of two connective 
tissue diseases (Table 2). The majonly of these patients developed SSc, SLE or a 
SSc-SLE overlap syndrome, while in none of the patients a diagnosis of DM or 
PM could be made. In the group of patients initially designated MCTD the time 
lapse between first clinical presentation and diagnosis of a classified connective 
tissue disease was on average 2.6 ± 3 years (median 2 years). The patients who 
remained classified as MCTD had a mean follow-up of 12.7 ± 4.2 years (median 
12 years). 
The initial charactenstics of these latter patients were not different from patients 
who evolved into a well-defined connective tissue disease (data not shown). 
Follow-up data of those patients, who fulfilled diagnostic entena of SLE, SSc or 
RA al first clinical presentation, are also shown in Table 2. It appeared that 
during follow-up four patients with SLE and one with RA also fulfilled classifica-
tion entena for SSc and one patient with RA fulfilled classification criteria of 
SLE, the patient with SSc developed signs and symptoms of RA. 
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Table 2: Diagnoses at first clinical presentation and at follow-up of 46 patients with 
Anü-(Ul)snRNP-anti bodies 
Number of patients and diagnosis 
at First clinical presentation 
Number of patients and 
diagnosis at follow-up 
33 MCTD 
5SLE 
2 SLE/SSc 
7 SSc 
3RA 
1 RA/SSc 
15 MCTD 
10SLE 
-> 6 SLE 
-> 4 SLE/SSc 
2 RA 
-> 1 RA 
-> 1 RA/SSc/SLE 
1 SSc 1 SSc/RA 
Finally, 31 (67%) of all anti-(Ul)snRNP antibody positive patients entered in this 
study fulfilled ARA diagnostic criteria for SLE, SSc, RA or a combination of 
(hese diseases. 
Autoantibody profiles 
In addition to anti-(Ul)snRNP antibodies other autoantibodies appeared to be 
present at first clinical presentation as well (Table 3). RF was the most prevalent 
antibody; it could be detected in sera of 26 (79%) patients with MCTD, of five 
(50%) patients with SLE and of both patients with RA, and of the one patient 
with SSc. Anti-dsDNA antibodies were the second most frequent autoantibodies 
found and occurred in three (9%) of the patients with MCTD and eight (80%) of 
patients with SLE. Other autoantibodies that could be detected each in one patient 
only were anli-Sm antibodies, anti-SSA and -SSB-antibodies and anticentromere 
antibodies. 
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Table 3: Concurrent autoantibodies In anti-(Ul)snRNP positive patients at first 
clinical presentation 
MCTD SLE RA SSc 
(n=33) (n=10) (n=2) (n=l) 
Rheumatoid factor 
Anti-dsDNA 
Anti-Sm 
Anti-SSA 
Anti-SSB 
Anticentromere 
Antitopoisomerase I 
For abbreviations see Table 1. 
During the follow-up period anti-(Ul)snRNP antibodies remained detectable in the 
serum of every patient. The three patients with MCTD and anti-dsDNA antibodies 
at presentation all developed SLE during follow-up. Patients with MCTD through­
out the follow-up period did not develop other autoantibodies than those present at 
clinical presentation. However, in four other patients out of the 18 patients with 
an initial diagnosis of MCTD who developed a classified connective tissue 
disease, autoantibodies appeared during follow-up (RF in two patients, one of 
whom developed SLE and one SSc; anti-dsDNA antibodies and anti-Sm/anti-
dsDNA antibodies both in one patient who developed SLE). 
In seven patients with an initial diagnosis of SLE other autoantibodies than those 
present at first clinical presentation appeared during follow-up; these autoanti­
bodies consisted of RF in three cases, anti-dsDNA in two and anti-SSA and anti-
Sm both in one patient. Patients with an initial diagnosis of SSc or RA did not 
develop other autoantibodies than those initially present. 
Treatment 
In most of the patients with MCTD (n=15) throughout the follow-up period, 
symptoms could be managed with a combination of NSAIDs and hydroxy­
chloroquine (n=14). Five (34%) patients received an additional treatment of 5 mg 
prednisone daily. In only two (13%) patients prednisone dosage was temporarily 
enhanced to 15 mg a day because of mild thrombocytopenia. Patients with an 
initial diagnosis of MCTD but who developed SLE or SSc, required treatment 
with high doses prednisone (>15 mg a day) and/or azalhioprine, methotrexate or 
26 5 2 ι 
3 8 1 -
1 
1 
1 
1 
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cyclophosphamide more frequently than those with persistent MCTD. Four of the 
patients who developed SLE and two of those who developed SSc received those 
treatments because of evolving glomerulonephritis, serositis or vasculitis. 
Discussion 
In this study, 13 of 46 patients with anti-(Ul)snRNP antibodies could be diag-
nosed as SLE, SSc or RA at first clinical presentation. This confirms other reports 
which state that anti-(Ul)snRNP antibodies are not specific to any of the connec-
tive tissue diseases'48'1 ". Moreover, in 18 (55%) of 33 patients with anti-(Ul)sn-
RNP antibodies with a diagnosis of MCTD according to Sharp's criteria at 
presentation, a diagnosis of SLE, SSc, RA or a combination of these disorders 
could be made during a minimal follow-up period of five years. This is in 
agreement with reports in the literature'6,713"161 and supports the concept that 
MCTD is a transient phase of a connective tissue disease, not yet having reached 
its final expression. 
None of the presenting symptoms in the MCTD patients appeared to be predicat-
ive for the evolution towards a classified connective tissue disease. However, the 
de novo appearance of specific autoantibodies during the course of the disease 
must alert the physician of an ongoing development towards SLE or RA. In some 
patients initially designated MCTD, the appearance of anti-dsDNA antibodies 
made a diagnosis of SLE possible. 
Patients initially diagnosed as MCTD who evolved into SLE, SSc, RA or a 
combination of these diseases, developed complications that required more 
aggressive treatment than was required for those with persistent MCTD. Anti-
(Ul)RNP-antibodies are therefore not associated with a favorable disease course 
as stated in the original report of MCTD by Sharp"' but refuted later"J2527). 
Anti-(Ul)RNP-anlibodies have been reported to appear or disappear during the 
course of disease'28'. In this study, however, anli-(Ul)RNP-antibodies persisted in 
all patients throughout the follow-up period, irrespective of treatment. Neither was 
a switch observed in antibody production from anti-(Ul)RNP to Sm or vice versa, 
as mentioned in several reports'28'2". During the follow-up other autoantibodies 
than those present at clinical presentation were produced by a number of patients 
initially diagnosed as MCTD who developed a classified connective tissue disease, 
as well as in those patients with a classified disease at presentation. 
We conclude that the majority of patients with anti-(Ul)snRNP antibodies have or 
will get a classified connective tissue disease such as SLE, SSc, RA or a combi-
nation of these diseases within five years after presentation. 
We agree with previously published proposals'30,3" to abandon the concept of 
MCTD as a distinct clinical entity and to reserve the demotion undifferentiated 
connective tissue disease for patients with signs and symptoms of a connective 
tissue disease not satisfying the established classification criteria for any of the 
connective tissue diseases, irrespective the presence of anli-(Ul)RNP antibodies. 
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Summary and Conclusions 

Summary and Conclusions 
The main objective of this thesis is to assess the efficacy and toxicity of low-dose 
MTX in the treatment of patients with systemic sclerosis (SSc). Further objectives 
are to assess the effects of MTX on extracellular matrix production of 
scleroderma fibroblasts, to investigate whether antitopoisomerase I antibody titers 
can be used in assessing response to treatment in SSc, and to confirm assumptions 
that patients with MCTD develop SSc in due course. 
Chapter I is a general introduction including definition, classification, 
epidemiology and prognosis, ctiopalhogenesis and treatment of SSc, and outcome 
measures used in SSc. Moreover, MTX and its use in rheumatic diseases is briefly 
discussed. 
A review of the literature regarding immunomodulatory treatment of SSc is 
presented in chapter II. In uncontrolled trials applying numerous immuno-
modulating drugs, such as chlorambucil, azathioprine, cyclophosphamide, 5-
fluoro-uracil and cyclosporine, a beneficial effect was claimed on the progression 
of SSc. However, on the rare occasion that a double-blind placebo controlled trial 
with any of these drugs was performed, these effects could not be substantiated. 
Low-dose MTX was reported once in the treatment of two patients with SSc; 
improvement was obtained in softening of the skin of the dorsum of the hands 
and in range of motions of the fingers. 
In chapter III we report on our first experiences with MTX treatment of scleroder-
ma patients. In chapter Ilia the first two scleroderma patients receiving MTX 
since Welin's case report in 1973, are described and in chapter Illb the results of 
an open 12 months study in eight scleroderma patients are reported. Patients 
received 15 mg MTX weekly except for one patient, who received 5 mg MTX 
weekly because of impaired renal function. It appeared that after 12 months a 
significant improvement occurred in skin thickening and maximal oral opening 
while no significant deterioration was detected in internal organ tests performed. 
First signs of improvement were usually noted after 3 months of treatment. We 
concluded that these data, obtained in an open study, suggested beneficial effects 
of MTX in the treatment of patients with SSc but that a double-blind placebo 
controlled study was necessary before definite conclusions could be drawn. 
Chapter IV describes the results of a double-blind randomized 48 week trial. In 
this trial MTX was compared to placebo in 29 patients with SSc. Patients were 
randomly allocated to treatment with either MTX or placebo, both of which were 
administered weekly by intramuscular injection. The weekly dose of MTX was 
initially 15 mg. The two groups were balanced for disease duration and extent of 
skin involvement. 
Clinical and laboratory evaluations were made monthly by the same investigator. 
After 24 and 48 weeks of treatment response to treatment was evaluated. Res-
ponse to treatment was defined as favorable if the total skin score (TSS), reflect-
ing the area and degree of skin involvement, or general well-being, as determined 
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by Ihe palicnt on a 100-mm visual analogue scale (VAS) improved by >30%, or if 
the diffusion capacity for carbon monoxide (DLC0) improved >15%. However, 
when digital ulcerations developed or persisted or when DLC0 decreased by >15%, 
despite improvement of TS S or VAS, the response was defined as unfavorable. 
Patients with favorable response after 24 weeks of treatment continued with the 
same drug for another 24 weeks. Nonresponders on placebo after 24 weeks were 
started on 15 mg MTX weekly; nonresponders on 15 mg MTX weekly received 
an increased dose of 25 mg weekly for the remaining 24 weeks of the trial. 
Seventeen patients were allocated to receive MTX, 12 to receive placebo. The 
difference in number of patients in both groups was caused by a misrecording of 
two patients in the MTX group, discovered after breaking the trial code after the 
final patient had completed the trial. 
During the first 24 weeks of the trial 2 patients in each treatment group had to be 
withdrawn from the study because of side effects (n=l), renal crisis (n=2) and 
death due to progressive disease (n=l). After breaking the code at week 48, it 
appeared that a significantly higher percentage of patients receiving MTX had 
responded according to the predefined criteria, as compared to the patients 
receiving placebo (53% versus 10%, P=0.03). Only one patient was left in the 
placebo group making comparison between placebo and MTX treatment groups at 
week 48 impossible. Between week 24 and 48, two patients receiving an enhanced 
dose of 25 mg MTX died, one presumably because of acute myocardial infarction, 
the other due to progression of the disease. At week 48, out of the 22 patients 
who had completed the trial and had been treated with MTX for at least 24 
weeks, 15 (68%) could be classified as responders. With respect to any of the 
variables tested, it appeared that significantly more women than men responded 
favorably (p=0.05) and that mean C4 levels were significantly higher at study 
entry in the responders. Moreover, antitopoisomerase I antibodies seemed to be 
identified more frequently in the nonresponders (p=0.06). 
Adverse reactions occurred only in patients receiving MTX and included: severe 
headache after each injection (n=l), necessitating discontinuance of MTX; 
transient elevations of liver enzymes (n=6) and pancytopenia (n=l). The latter two 
side effects normalized within 2 to 4 weeks after the trial medication was 
withheld and did not recur after resuming the same dose of MTX. 
We concluded that this double-blind trial demonstrated efficacy of MTX in the 
treatment of patients with SSc and that the number of adverse reactions was 
relatively high but, in general, minor and manageable. 
In chapter V we determined the effects of increasing concentrations of MTX on 
the proliferation and GAG synthesis of cultured dermal fibroblasts from patients 
with scleroderma. Fibroblasts in SSc are known to produce excessive amounts of 
extracellular matrix components, mainly collagen, glycosaminoglycans (GAG) and 
fibronectin. Cultured fibroblasts from nine patients with scleroderma and nine 
normal volunteers were grown for 72 hours in media containing various con-
centrations of MTX. The GAG synthesis in each cell was measured after in-
cubating the fibroblasts with [3H]-glucosaminc and [35S]-sulfatc. We found a 
negative correlation between the concentration of MTX and numbers of fibro-
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blasts from patients with scleroderma and normal controls. A positive correlation 
was found between GAG synthesis in each cell and increasing MTX con-
centrations in fibroblasts from SSc patients and normal controls. It was concluded 
that the beneficial effect of MTX on skin fibrosis in scleroderma is most probably 
not the result of direct inhibition of GAG synthesis of fibroblasts. 
Chapter VI presents the expression of a cDNA clone encoding 695 carboxyl-
terminal amino acids of human DNA topoisomerase I (topoi) in Escherichia coli. 
Immunoreaclivity with this recombinant protein (the HTopoA protein) was 
obtained in more than 96% of the anti-HeLa topol-positive sera from patients with 
a connective tissue disease. All sera from patients with SSc and reacting with 
HeLa topoi reacted with the HTopoA protein. Sera from patients with SSc not 
containing anlitopoisomerase I antibodies did not display immunoreactivity with 
the HTopoA protein. At least three different autoimmune epitope regions on the 
HTopoA protein could be assigned and it was shown that over a period of 5 years 
the amount of antitopoisomerase I antibodies against these regions may fluctuate. 
Chapter Vila reports on the effects of plasma exchange (PE) on the synthesis of 
antitopoisomerase I antibody production. Levels of autoantibody concentrations 
during PE-thcrapy of scleroderma patients have been used to monitor the efficacy 
of PE. The case of a 50 year old woman is presented with systemic sclerosis and 
progression of skin thickening. After four weeks of azathioprine treatment, PE 
was started and during a 29 day period 11 PE sessions were performed. Im-
mediately before and after each PE, antitopoisomerase I antibody concentrations 
were measured using an ELISA with HTopoA as antigen source. After each PE, 
IgG and IgA antitopoisomerase I antibody levels decreased on average 40% and 
51% respectively. However, within 1 to 5 days after each PE, antitopoisomerase I 
antibody titers increased to 80% - 125% of pre-PE levels. It was concluded that 
rebound of antitopoisomerase I and presumably all other autoantibodies should be 
considered in PE treatment of patients with SSc. 
In chapter Vllb the effects of low dose MTX treatment on antitopoisomerase I 
antibody titers are reported. In sera from 16 scleroderma patients who participated 
in the double-blind trial comparing MTX with placebo, antitopoisomerase I 
antibodies could be detected. At study entry and after 24 and 48 weeks, antitopo-
isomerase I antibody titers were measured using an ELISA with HTopoA as 
antigen source. We observed an equal decrease of antitopoisomerase I antibody 
titers in sera from patients treated with MTX or placebo. Likewise, a similar 
reduction of antitopoisomerase I antibody titers was found in sera from patients 
responding on MTX treatment and in patients not responding. The conclusion 
drawn from these findings was that antitopoisomerase I antibody titers are not 
useful for monitoring MTX treatment in SSc. 
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In chapter Ш the long term follow-up of patients with anli-(Ul)snRNP an­
tibodies is described. Anti-(Ul)snRNP antibodies are considered to be the 
hallmark of mixed connective tissue disease (MCTD). However, since the original 
description of MCTD by Sharp and co-workers in 1972, the concept of MCTD 
being a distinct disease entity has been questioned. We examined charts of forty-
six patients with anti-(Ul)snRNP antibodies and a follow-up period of at least 5 
years. It was found that at first clinical presentation 28% of patients with anti-
(Ul)snRNP antibodies fulfilled ARA classification criteria for systemic lupus 
erythematosus (SLE), SSc or rheumatoid arthritis (RA). At the end of the follow-
up period, 67% met ARA classification criteria for SLE, SSc, RA or a combina­
tion of these diseases. This transformation from MCTD towards a defined 
connective tissue disease occurred on average 2.6 years after first clinical presen­
tation. We concluded that MCTD is a transient phase of a connective tissue 
disease and agreed with previous proposals to abandon the concept of MCTD. 
General conclusions of this thesis are: 
Methotrexate is effective in the treatment of patients with SSc; 
Methotrexate is well tolerated but the occurrence of hematological side 
effects and hepatic function disturbances necessitate close monitoring; 
The reduction of skin fibrosis by MTX is unlikely to be caused by direct 
inhibition of glycosaminoglycan production of fibroblasts; 
A recombinant DNA topoisomerase I (the HTopoA protein) reacts with all 
sera from patients with SSc that react with HeLa topoi; 
Antitopoisomerase I antibody titers are not helpful in assessing clinical 
response to either plasma exchange therapy or MTX treatment; 
Mixed connective tissue disease is a transient phase of a connective tissue 
disease. 
Aims for future research 
One of the objectives for future research is to compare MTX treatment with 
presumed beneficial treatments, such as D-penicillamine, cyclosporine or inter-
feron-γ. Such trials require large numbers of patients. Given the rarity of the 
disease it is difficult to recruit patients for clinical trials in one single center and 
multicentre studies are necessary. Multicentre studies urge standardization of 
outcome measures. It will be the major goal of centers involved in clinical trials 
in scleroderma, to reach consensus on which outcome measures will be used in 
future trials and to standardize these outcome measures. 
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Samenvatting 
Sclerodermie of systemische sclerose is een gegeneraliseerde bindwcefsclaan-
doening gekenmerkt door fibroscring van de huid, spieren, gewrichten en in-
wendige organen, met name slokdarm, longen, hart en nieren, hetgeen leidt tot 
een stoornis in de functie van de betreffende organen. Bij ongeveer 90% van de 
patiënten met sclerodermie treedt het fenomeen van Raynaud op. De fibrosering 
wordt veroorzaakt door een overmatige ophoping van extracellulaire matrixbe-
slanddelen zoals collageen, fibronectine en glycosaminoglycanen. De oorzaak van 
deze aandoening is onbekend; echter de bij sclerodermie gevonden afwijkingen in 
de extracellulaire matrix, in de microcirculatie en het immuunapparaat hebben tot 
de volgende hypothese geleid: cndolheelcellen worden door onbekende factoren 
beschadigd waardoor het immuunsysteem geactiveerd wordt met een toename van 
de endotheelschade als gevolg. Hierdoor komen cytotoxische producten vrij die 
fibroblastcn stimuleren tot zowel proliferatie als overmatige depositie van extra-
cellulaire matrixbe-standdelen, hetgeen uiteindelijk leidt tot fibrose. 
Op grond van de uitgebreidheid van de huidafwijkingen wordt sclerodermie 
onderverdeeld in een diffuse vorm, waarbij de huidfibrose zich tot proximaal van 
de ellebogen en knieën uitbreidt, en een gelimiteerde vorm, waarbij de huidfibrose 
zich beperkt tot de onderarmen. Antitopoisomerase I antistoffen zijn aantoonbaar 
in ongeveer 50% van de sera van patiënten met een diffuse vorm, anlicentromeer 
in ongeveer 50% van de patiënten met een gelimiteerde vorm. Andere autoanti-
stoffen, zoals anti-Th, anti-(U3)RNP en anti-PMScl, worden slechts bij 5% van de 
sclerodermiepatiënten aangetoond. 
Sclerodermie is een zeldzame aandoening; in verschillende studies wordt een 
incidentie opgegeven variërend van 4 tot 12 per miljoen per jaar. Sclerodermie 
komt in alle rassen voor, 3 tot 4 keer vaker bij vrouwen dan bij mannen en begint 
veelal tussen het veertigste en vijftigste levensjaar. 
Het natuurlijk ziektebeloop is wisselend en kan variëren van een spontane 
remissie, hetgeen zelden voorkomt, tot geleidelijke of snelle progressie van huid-
en inwendige orgaan afwijkingen. De mortaliteit is aanzienlijk; in verscheidene 
epidemiologische studies wordt cen cumulatieve 5-jaars overleving vermeld van 
34-73%. Aantasting van inwendige organen, hoge leeftijd, mannelijk geslacht, 
uitgebreidheid van de huidafwijking en aanwezigheid van antitopoisomerase I 
anlilichamen zijn prognostisch ongunstige factoren. 
Verscheidene medicamenten worden toegepast in de behandeling van sclero-
dermie, veelal op grond van positieve bevindingen in case reports of on-
gecontroleerd onderzoek. Echter nimmer werd in dubbelblind, placebo gecontro-
leerd onderzoek effectiviteit van deze medicamenten aangetoond. Onderzoek naar 
de effectiviteit van een geneesmiddel bij sclerodermie wordt bemoeilijkt door het 
wisselende ziektebeloop met soms spontane verbetering, en de wisselende mate 
van progressie van sclerodermie; een dergelijk onderzoek dient derhalve bij 
voorkeur dubbelblind en placebo gecontroleerd te zijn. 
Methotrexate is een foliumzuurantagonist en interfereert in de synthese van DNA 
en RNA. Mclhotrcxaat is een effectieve behandeling van reumatische aandoe-
ningen zoals reumatoïde artritis, polymyositis en dermatomyositis. De toegepaste 
doseringen hierbij variëren van 7.5 mg/weck tot 50 mg/week. Het werkingsmecha-
nisme van methotrexaat bij deze aandoeningen is vooralsnog onbekend; de relatief 
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snelle klinische respons na start van de behandeling en de eveneens snel optre-
dende exacerbatie van ziekteactivitcit na staken van methotrexaat suggereren een 
anti-inflammatoir effect. 
Slechts eenmaal is methotrexaat in de literatuur beschreven als mogelijke behan-
deling van sclerodermie. Het betreft een onderzoek uit 1973 waarbij twee patiën-
ten, één met een gelimiteerde vorm van sclerodermie en één met een diffuse vorm 
gecompliceerd door longfibrose, werden behandeld met 25 mg methotrexaat om 
de 14 dagen gedurende een periode van 6 maanden. Bij beide patiënten verbeterde 
de algehele conditie, verminderde de huidfibrose en nam de intensiteit van het 
fenomeen van Raynaud af. 
Het voornaamste doel van dit proefschrift is onderzoek naar de effectiviteit en de 
toxiciteit van methotrexaat in de behandeling van patiënten met sclerodermie. 
Andere doeleinden zijn onderzoek naar effecten van methotrexaat op de produktie 
van extracellulaire matrix door fibroblasten, onderzoek naar de waarde van 
antitopoisomerase I antistoftiters om respons op behandeling te meten en onder-
zoek naar het ziektebeloop van patiënten met mixed connective tissue disease, een 
aandoening klinisch gekenmerkt door verschijnselen van sclerodermie, syste-
mischc lupus erythematosus en polymyositis. 
In Hoofdstuk I wordt een definitie gegeven van het ziektebeeld sclerodermie en 
wordt nader ingegaan op de door de American Rheumatism Association voorge-
stelde voorlopige classificatiecriteria voor sclerodermic. Tevens wordt een over-
zicht van de literatuur gegeven betreffende eliopathogenese, epidemiologie, 
outcome variabelen, behandeling en prognose van sclerodermie. Methotrexaat en 
de toepassing ervan in reumatische aandoeningen worden in het kort besproken. 
Hoofdstuk II is een overzicht van de literatuur over de behandeling van scleroder-
mie met immunomodulerende geneesmiddelen. Beschreven wordt dat in on-
gecontroleerd onderzoek positieve effecten op de progressie van sclerodermie 
worden gemeld van immunomodulerende medicamenten zoals azathioprine, 
chlorambucil, cyclophosphamide, 5-fluoro-uracil en cyclosporine. Dubbelblind, 
placebo gecontroleerd onderzoek werd slechts uitgevoerd met chlorambucil en 5-
fluoro-uracil, waarbij geen verschillen werden gevonden tussen deze medicamen-
ten en placebo. 
In Hoofdstuk lila beschrijven we de eerste twee patiënten met sclerodermie die 
sedert de publikatie van Welin in 1973 methotrexaat kregen toegediend. Aan-
gezien tijdens behandeling met methotrexaat de huidafwijkingen bij deze twee 
patiënten afnamen en er geen progressie van aantasting van inwendige organen 
optrad, werd een pilot studie gestart, waarvan de resultaten worden beschreven in 
Hoofdstuk Illb. Acht patiënten werden behandeld met 15 mg methotrexaat per 
week, met uitzondering van één patiënt, die een gereduceerde dosis kreeg van 5 
mg per week in verband met een gestoorde nierfunctie. Na 12 maanden behan-
deling bleek er een significante verbetering te zijn opgetreden in de uitgebreidheid 
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ел mate van huidfibrosering, en van de maximale lip-lip afstand. Significante 
veranderingen in de onderzochte inwendige orgaanfuncties werden niet waar­
genomen. We trokken de conclusie dat methotrexaat mogelijk een effectieve 
behandeling van sclerodermie is, doch dat dubbelblind, placebo-gecontroleerd 
onderzoek noodzakelijk is om dit vermoeden te bevestigen. 
De resultaten van een 48 weken durend, dubbelblind, placebo gecontroleerd en 
gerandomizeerd onderzoek worden weergegeven in Hoofdstuk IV. Negenentwintig 
patiënten met sclerodermie werden behandeld met wekelijkse intramusculaire 
injecties met 15 mg methotrexaat of placebo. Beide groepen werden gerando-
mizeerd naar ziekleduur en uitgebreidheid van de huidafwijkingen. Bij patiënten, 
bij wie een gunstig effect werd waargenomen na 24 weken behandeling, werd 
dezelfde medicatie gedurende 24 weken gecontinueerd. Bij patiënten zonder 
gunstig effect op placebo werd de behandeling voortgezet met 15 mg metho-
trexaat, bij patiënten zonder gunstig effect op 15 mg methotrexaat werd de 
dosering methotrexaat verhoogd tot 25 mg. Een gunstig effect op de toegediende 
medicatie was gedefinieerd als een verbetering van de total skin score (TSS) of 
van de visual analogue scale (VAS) betreffende algeheel welbevinden van ten-
minste 30%, of een verbetering van de CO-diffusie capaciteit van de longen 
(DLC0) van tenminste 50%, mits er geen digitale ulceraties ontstonden of persis-
teerden en mits de DLC0 niet verslechterde met 15% of meer. Twaalf patiënten 
kregen placebo toegediend en 17 patiënten methotrexaat tijdens de eerste 24 
weken van het onderzoek. Dit verschil in aantal patiënten in beide groepen was 
het gevolg van een verkeerde toewijzing van twee patiënten in de methotrexaat-
groep, hetgeen ontdekt werd bij het verbreken van de behandelingscodc nadat de 
laatste patiënt hel onderzoek voltooid had. Twee patiënten uit beide groepen 
voltooiden dit deel van het onderzoek niet: één patiënt overleed door car-
diorespiratoire insufficiëntie, bij twee patiënten trad er een renale crisis op en bij 
één patiënt waren er bijwerkingen op de trialmedicatie. Bij het verbreken van de 
behandelingscode aan het einde van de studie bleek dat na 24 weken een sig-
nificant groter aantal patiënten die behandeld waren met methotrexaat (n=8, 53%) 
gunstig te reageren in vergelijking met de placebo behandelde patiënten (n=l, 
10%, p=0.03). Negen patiënten die onvoldoende gereageerd hadden op placebo 
werden van week 24 tot week 48 behandeld met 15 mg methotrexaat per week en 
zeven patiënten die onvoldoende gereageerd hadden op 15 mg methotrexaat met 
25 mg methotrexaat per weck. Twee patiënten uit de laatste groep overleden 
tijdens de tweede 24 weken van het onderzoek: één ten gevolge van progressie 
van de sclerodermic, de ander overleed acuut, vermoedelijk ten gevolge van een 
myocardinfarct. Aan het einde van het onderzoek bleken 15 van de 22 (68%) 
patiënten die het onderzoek hadden voltooid en gedurende ten minste 24 weken 
behandeld waren met methotrexaat te voldoen aan de respons criteria. Op week 48 
bleek er in deze groep een significante verbetering te zijn opgetreden in TSS 
(p=0.04), VAS (p=0.02) en grijpkracht van de rechter hand (p=0.02); er trad geen 
verslechtering op in de onderzochte inwendige orgaanfuncties. Tevens bleek dat 
vrouwen significant beter reageerden op behandeling met methotrexaat dan 
mannen (p=0.05) en dat de gemiddelde C4 waarden in het begin van de studie 
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significant hoger waren in de patiënten, die gunstig reageerden op methotrexaat. 
Bij de patiënten die niet reageerden op de behandeling met methotrexaat konden 
vaker, zij hel niet significant, antitopoisomerase I antistoffen worden aangetoond 
(p=0.06). Tijdens dit onderzoek traden slechts bijwerkingen op bij patiënten, 
behandeld met methotrexaat. Deze bijwerkingen bestonden uit hevige hoofdpijn na 
elke injectie bij een patiënt, waardoor methotrexaat gestaakt diende te worden; 
passagère leverfunctiestoomissen bij zes patiënten en pancytopenie bij één. Deze 
laatste (wee bijwerkingen verdwenen 2 tot 4 weken na het staken van de metho-
trexaat en traden niet opnieuw op na hervatting van de methotrexaat. 
De conclusie van deze studie was, dat methotrexaat een effectieve behandeling is 
voor sclerodermie, en dat de bijwerkingen, hoewel ze relatief vaak voorkwamen, 
over het algemeen niet emstig waren en verdwenen na staken van de metho-
trexaat. 
In Hoofdstuk V worden de effecten onderzocht van verschillende doseringen 
methotrexaat op de proliferatie en synthese van glycosaminoglycanen van in 
kweek gebrachte, uit de huid geïsoleerde fibroblastcn van patiënten met sclero-
dermie en gezonde controles. Uit eerder onderzoek is bekend dat fibroblasten van 
sclerodermie patiënten in verhoogde mate collageen, glycosaminoglycanen en 
fibronectine produceren. Wij brachten fibroblastcn in kweek van negen patiënten 
en negen gezonde vrijwilligers; deze fibroblasten werden vervolgens gedurende 72 
uren gekweekt in media met verschillende concentraties methotrexaat. De synthese 
van glycosaminoglycanen per fibroblast werd bepaald na incubatie van de 
fibroblasten met [3H]-glucosaminc en ["Hl-sulfaat. Er bleek een negatieve 
correlatie te bestaan tussen de hoogte van de methotrexaat concentratie en het 
aantal fibroblasten zowel bij patiënten als bij controles, en er werd een positieve 
correlatie gevonden tussen hoogte van de methotrexaatconcenlratie en de synthese 
van glycosaminoglycanen per fibroblast, eveneens zowel bij patiënten als bij 
controles. Hieruit werd geconcludeerd dat de gunstige effecten van methotrexaat 
op de fibrosering van de huid bij patiënten met sclerodermie zeer waarschijnlijk 
niet hel gevolg zijn van een rechtstreekse remming van de glycosaminoglycaan-
synthese van fibroblasten. 
Hoofdstuk VI beschrijft de expressie van een cDNA clone in Escherichia Coli, die 
695 aminozuren van het humane lopoisomerase I (topoi) codeert. Dit recom-
binante eiwit (HTopoA eiwit) bleek te reageren met 96% van de anti-HcLa topol-
positieve sera van patiënten met een bindweefselaandocning. Alle serummonsters 
van patiënten met een sclerodermic die reageerden met HeLa topoi reageerden 
ook met het HtopoA eiwit. Serummonsters van sclerodermiepatiënten waarin geen 
antitopoisomerase I antilichamen aantoonbaar waren, reageerden niet met het 
HTopoA eiwit. Er konden ten minste drie verschillende epitopen op het HTopoA 
eiwit benoemd worden en aangetoond werd dat de concentratie antitopoisomerase 
I anlilichamen gericht tegen deze epitopen in lijd kan fluctueren. 
Hoofdstuk Vila behandelt het effect van plasmafcrcse op de synthese van 
antitopoismcrase Ι anlilichamen, waargenomen bij een patiënt met ernstige sclero-
126 
Samenvatting 
derm ie, die in een periode van 29 dagen 11 maal een plasmafcrese onderging. Na 
elke plasmafercse bleek de concentratie van IgG- en IgA-antitopoisomerasc I 
antistoffen, gemeten met een ELISA met HtopoA als antigeen, gemiddeld 40% 
resp. 51% gedaald te zijn. Binnen 1 tot 5 dagen na elke plasmafercse bleken de 
anlilopoisomerase I antistofliters te stijgen tot 80% - 125% van de waarden 
verkregen vóór plasmaferese. Hieruit werd de conclusie getrokken, dat bij de 
behandeling van sclerodermie met plasmafcrese rekening gehouden moet worden 
met een rebound van anlilopoisomerase I antistoffen, en de concentratie van deze 
antistoffen niet gebruikt kan worden om een eventueel effect van de plasmaferese 
te meten, zoals in de literatuur wordt geopperd. 
In Hoofdstuk Vllb wordt het effect onderzocht van lage doseringen methotrexaat 
op de concentratie van antitopoisomerase I antistoffen. In serum van 16 patiënten, 
die deelnamen aan hel dubbelblinde placebo gecontroleerde onderzoek, konden 
anlilopoisomerase I antistoffen worden aangetoond. Bij aanvang, na 24 en 48 
weken werden hiervan de titers bepaald met een ELISA met HtopoA als antigeen. 
Deze tilers daalden zowel bij patiënten die behandeld werden met methotrexaat als 
met placebo, en zowel bij patiënten die gunstig reageerden op de behandeling met 
mclholrcxaat als patiënten die niet reageerden. Significante verschillen tussen de 
verschillende groepen werden niet waargenomen. Wij concludeerden dat hel niet 
zinvol was om anlilopoisomerase I antistoftiters te vervolgen tijdens behandeling 
mcl mclholrcxaat van patiënten met een sclerodermic 
Ten slotte worden in Hoofdstuk VIII de resultaten van een onderzoek beschreven, 
waarin 46 patiënten met anti-(Ul)snRNP antistoffen, die beschouwd worden als 
kenmerkend voor het ziektebeeld mixed connective tissue disease (MCTD), 
gedurende ten minste 5 jaren zijn vervolgd. Bij ccrsle polikliniek bezoek bleek 
28% van deze patiënten te voldoen aan criteria voor systemische lupus erythema-
tosus, sclerodermie of reumatoïde artritis, zoals opgesteld door de American 
Rheumatism Association. Aan het einde van dit follow-up onderzoek voldeed 67% 
van de patiënlcn aan deze criteria, of aan een combinatie hiervan. MCTD blijkt 
dus in de meerderheid van de gevallen een beginstadium van een geclassificeerde 
bindwccfselaandoening te zijn en de term MCTD kan derhalve beter vervangen 
worden door unclassified connective tissue discase (UCTD). 
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Academisch Ziekenhuis St Radboud in Nijmegen, niet in het minst door de 
prettige sfeer die er heerst op de werkvloer. Hieraan wordt door een ieder op 
specifieke wijze bijgedragen. Alle collega's en medewerkers; bedankt en houden 
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Niels, Luuk en Marlous maakten regelmatig op vertederende wijze duidelijk dal er 
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studeerde geneeskunde en culturele antropologie aan de Katholieke Universiteit 
Nijmegen. In 1981 legde hij het artsexamen af. Vanaf 1 november 1981 volgde 
hij de opleiding Interne Geneeskunde in het Ziekenhuis Ziekenzorg te Enschede 
(opleider: Dr. S.G.T. Hulst) en werd in 1986 ingeschreven als internist. 
Vervolgens werd de opleiding tot reumatoloog gevolgd op de afdeling reumatolo­
gie van het Academisch Ziekenhuis, St Radboud in Nijmegen (opleider: Prof.dr. 
L.B.A. van de Putte), welke in 1989 voltooid werd. Het onderzoek in dit proef­
schrift beschreven werd verricht tussen 1989 en 1993. 
Sedertdien is hij als stafmedewerker verbonden aan de afdeling reumatologie. 
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i 
STELLINGEN 
behorende bij het proefschrift 
Systemic sclerosis: Effects of treatment with methotrexate 
I 
Methotrexaat is een effectieve behandeling voor sclerodermie. 
II 
De effectiviteit van methotrexaat bij sclerodermie berust niet op een rechtstreekse 
remming van de glycosaminoglycaansynthese van fibroblasten. 
III 
Het is niet zinvol om antitopoisomerase I antistoftiters te bepalen ter beoordeling van 
de effectiviteit van een behandeling bij sclerodermie. 
IV 
De term mixed connective tissue disease (MCTD) dient vervangen te worden door 
unclassified connective tissue disease (UCTD). 
V 
De alom heersende opvatting dat een operatieve wond bij sclerodermiepatiënten slecht 
geneest, is onjuist. 
VI 
Door het verder inkorten van de studieduur zal de student zich niet meer met "buiten-
schoolse" activiteiten kunnen bezighouden. Hierdoor worden bij aanvang van de stu-
die gratis oogkleppen aangeboden. 
VII 
Streven naar perfectie mag een doel zijn, nimmer een obsessie. 
Vili 
Kennis van tekstverwerkingsprogrammatuur bij artsen heeft in niet geringe mate bij-
gedragen aan de toename van vakJiteratuur in het afgelopen decennium. 
IX 
Door de welkome opmars van het vrouwelijk geslacht in de specialistische gezond-
heidszorg, zullen artsen van het mannelijk geslacht in de toekomst wellicht met 
broeder worden aangesproken. 
X 
Hardnekkige verkeersovertreders, die het verkeer als een spel beschouwen, kunnen 
slechts gestraft worden door ze hun speeltuig te ontnemen. 
XI 
Wanneer de r in de maand verschijnt zijn borstrokken en lange onderbroeken beslist 
noodzakelijke kledingstukken om buiten de reguliere werktijden werkzaamheden op 
je eigen werkkamer in het Academisch Ziekenhuis St Radboud uit te voeren. 
Nijmegen, 10 november 1994. 
Frank van den Hoogen 


